US20040047903A1 - D and L etherlipid stereoisomers and liposomes - Google Patents
D and L etherlipid stereoisomers and liposomes Download PDFInfo
- Publication number
- US20040047903A1 US20040047903A1 US10/647,382 US64738203A US2004047903A1 US 20040047903 A1 US20040047903 A1 US 20040047903A1 US 64738203 A US64738203 A US 64738203A US 2004047903 A1 US2004047903 A1 US 2004047903A1
- Authority
- US
- United States
- Prior art keywords
- liposome
- phosphatidylethanolamine
- lipid
- zero
- ether lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 118
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 47
- -1 ether lipid Chemical class 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 239000000232 Lipid Bilayer Substances 0.000 claims abstract description 17
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 16
- 229930182558 Sterol Natural products 0.000 claims abstract description 14
- 235000003702 sterols Nutrition 0.000 claims abstract description 14
- 150000003432 sterols Chemical class 0.000 claims abstract description 14
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000012867 bioactive agent Substances 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 14
- 150000002170 ethers Chemical class 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 7
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 7
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002691 unilamellar liposome Substances 0.000 claims description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 50
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- 231100000419 toxicity Toxicity 0.000 description 18
- 230000001988 toxicity Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000008280 blood Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 7
- OGBUMNBNEWYMNJ-NRFANRHFSA-N 1-O-octadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](O)CO OGBUMNBNEWYMNJ-NRFANRHFSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 240000005578 Rivina humilis Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 229950011461 edelfosine Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N stearyl monoglyceride Natural products CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- WPDRLJPASQLFJY-LDLOPFEMSA-N (2r)-1-octadecoxy-3-trityloxypropan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC[C@H](O)COCCCCCCCCCCCCCCCCCC)C1=CC=CC=C1 WPDRLJPASQLFJY-LDLOPFEMSA-N 0.000 description 4
- JWBOVDKFGDXGCR-QFIPXVFZSA-N (2s)-2-methoxy-3-octadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OC JWBOVDKFGDXGCR-QFIPXVFZSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000714177 Murine leukemia virus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- UELKEKWDSAUZCA-UHFFFAOYSA-N nonadecane-1-sulfonic acid Chemical compound CCCCCCCCCCCCCCCCCCCS(O)(=O)=O UELKEKWDSAUZCA-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 150000001991 dicarboxylic acids Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 238000012809 post-inoculation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PYTMBSDYMPHFOQ-UHFFFAOYSA-N 2,2,2-trichloro-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=C(NC(=O)C(Cl)(Cl)Cl)C=C1 PYTMBSDYMPHFOQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- KFRDUYMVLLZXED-RRHRGVEJSA-N [[(2r)-2-methoxy-3-octadecoxypropoxy]-diphenylmethyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC)C1=CC=CC=C1 KFRDUYMVLLZXED-RRHRGVEJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 150000002270 gangliosides Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001223 polyethylene glycol Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 2
- 238000003210 sulforhodamine B staining Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- JULIAXTVJPYWGG-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCC(CO[PH](=O)OC)OC Chemical compound CCCCCCCCCCCCCCCCCCOCC(CO[PH](=O)OC)OC JULIAXTVJPYWGG-UHFFFAOYSA-N 0.000 description 1
- CPRVGUDKCVVKBO-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCC(CO[PH](=O)OOC)OC Chemical compound CCCCCCCCCCCCCCCCCCOCC(CO[PH](=O)OOC)OC CPRVGUDKCVVKBO-UHFFFAOYSA-N 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000015083 Choline-Phosphate Cytidylyltransferase Human genes 0.000 description 1
- 108010078853 Choline-Phosphate Cytidylyltransferase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000011107 Diacylglycerol Kinase Human genes 0.000 description 1
- 108010062677 Diacylglycerol Kinase Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102000011720 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 1
- RNVYQYLELCKWAN-YFKPBYRVSA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@H](CO)O1 RNVYQYLELCKWAN-YFKPBYRVSA-N 0.000 description 1
- SFHBFVCPFPVTOL-KXHLAXDASA-N [H][C@@](COCCCCCCCCCCCCCCCCCC)(COP(=O)([O-])OCC[N+](C)(C)C)OC.[H][C@](COCCCCCCCCCCCCCCCCCC)(COP(=O)([O-])OCC[N+](C)(C)C)OC Chemical compound [H][C@@](COCCCCCCCCCCCCCCCCCC)(COP(=O)([O-])OCC[N+](C)(C)C)OC.[H][C@](COCCCCCCCCCCCCCCCCCC)(COP(=O)([O-])OCC[N+](C)(C)C)OC SFHBFVCPFPVTOL-KXHLAXDASA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002459 polyene antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- PFPGMFFYYMIGGO-KWIZKVQNSA-J tetrapotassium [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O PFPGMFFYYMIGGO-KWIZKVQNSA-J 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Definitions
- the invention relates to a liposome comprising an ether lipid stereoisomer in the lipid bilayer of the liposome.
- the invention also encompasses pharmaceutical compositions comprising the liposome and methods of treating an animal with the liposome.
- Pharmaceutical therapeutics useful in the treatment of cancers or inflammatory conditions generally aim to slow the growth of, or destroy cancer cells or modulate the cells responsible for inflammatory responses.
- Optimal therapeutics for instance cancer chemotherapy provides the decrease or eradication of cancer cell growth while avoiding or diminishing collateral damage to normal cells and tissues.
- the most effective anticancer agents are able to selectively target cancer cells while leaving normal cells relatively unaffected.
- Some etherlipids have been shown to be effective anticancer agents. However, the use of most etherlipids in vivo (to treat animals) has been accompanied by certain levels of toxicity to normal cells. Etherlipids are amphipathic lipids with ether linkages connecting their hydrocarbons with their molecular backbones.
- PAF platelet activating factor
- Ether lipids can accumulate in cell membranes, following which the lipids may affect the cells in a number of ways.
- Cell membrane accumulation can lead to disturbance of membrane lipid organization by a detergent-like activity of ether lipids; membrane structure, and hence, cell stability, can be disrupted by this activity.
- Phospholipid metabolism can also be disrupted, as the activities of several of the enzymes involved, e.g., CTP:phosphocholine cytidyl transferase, diacylglycerol kinase, sodium/potassium adenosine triphosphate phosphatase, acyl transferases, lysophospholipase, and phospholipases C and D, are inhibited in the presence of ether lipids.
- Ether lipids can also affect transmembrane signaling pathways, nutrient uptake, cellular differentiation and apoptosis.
- ether lipids are believed to be cytotoxic to cancer cells, and have been shown to be effective anticancer agents in animals (see, for example, Lohmeyer and Bittman, 1994; Lu et al. (1994a); Lu et al. (1994b); Dietzfelbinger et al. (1993); Zeisig et al. (1993); Berdel (1991); Workman (1991); Workman et al. (1991); Bazill and Dexter (1990); Berdel (1990); Guivisdalsky et al. (1990a); Guivisdalsky et al. (1990b); Powis et al. (1990); Layton et al. (1980); Great Britain Patent No.
- ether lipids are generally not toxic to most normal cells. Ether lipids' ability to act selectively on cancer cells is believed to be due to the cancer cells' lack of the alkyl cleavage enzymes necessary for hydrolysis of the lipids; the resulting intracellular lipid accumulation can disrupt the cells' functioning in a variety of ways. Normal cells typically possess these enzymes, and hence, are able to prevent the intracellular accumulation of ether lipids.
- lipid-based carriers e.g., liposomes.
- Such carriers can buffer drug toxicity, for example, by sequestering the drug in the carrier such that the drug is unavailable for inducing toxicity.
- Lipid carriers can also buffer drug-induced toxicity by interacting with the drug such that the drug is then itself unable to interact with the cellular targets through which it exerts its cytotoxic effects.
- the carriers also maintain the ability of the drugs to be therapeutically effective when released therefrom, e.g., when the carriers are broken down in the vicinity of tumors.
- U.S. Pat. No. 5,762,958 incorporated herein by reference, describes a liposome having an ether lipid as a component of the liposome's lipid bilayer. Such liposomes reduce the toxicity of the ether lipids without inhibiting their anti-cancer efficacy. Nevertheless, there is no suggestion in U.S. Pat. No. 5,762,958 that the chirality of the ether lipid would have any effect on the toxicity of the liposomal formulation.
- This invention provides a liposome having a lipid bilayer which comprises: an ether lipid having either a D or L chirality.
- the lipid bilayer of the liposome comprises at least one lipid in addition to the D or L etherlipid.
- the liposome comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine (also referred to herein as the “headgroup-derivatized lipid”), and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid.
- the ether lipid has the following formula:
- Y 1 is (CH 2 ) n1 (CH ⁇ CH) n2 (CH 2 ) n3 (CH ⁇ CH) n4 (CH 2 ) n5 (CH ⁇ CH) n6 (CH 2 ) n7 (CH ⁇ CH) n8 (CH 2 ) n9 .
- n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 3 to 23
- n1 is zero or an integer of from 1 to 22
- n3 is zero or an integer of from 1 to 19
- n5 is zero or an integer of from 1 to 16
- n7 is zero or an integer of from zero to 16
- n9 is zero or an integer of from 1 to 10
- each of n2, n4, n6 and 8 is independently zero or 1.
- Y 2 is CH 3 or CO 2 H.
- Z is oxygen or sulfur.
- Z is 0; accordingly, this invention's glycerol-based etherlipids preferably have a methoxy group at the sn-2 position of their glycerol backbone.
- the etherlipid is a D or L stereoisomer of the formula
- the liposome is a unilamellar liposome having a diameter of from greater than about 50 nm to less than about 200 nm
- the underivatized phosphatidylcholine is an unsaturated or partially unsaturated phosphatidylcholine, more preferably, dioleoyl phosphatidylcholine
- the sterol is cholesterol.
- the headgroup derivatized lipid preferably comprises a phosphatidylethanolamine (“PE”) selected from the group consisting of dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and dioleoyl phosphatidylethanolamine, and a dicarboxylic acid selected from the group consisting of glutaric acid, sebacic acid, succinic acid and tartaric acid. More preferably, the PE is dioleoyl phosphatidylethanolamine and the dicarboxylic acid is glutaric acid.
- PE phosphatidylethanolamine
- dicarboxylic acid selected from the group consisting of glutaric acid, sebacic acid, succinic acid and tartaric acid.
- Preferred embodiments of this invention's liposome have bilayers containing dioleoyl phosphatidylcholine as the underivatized PC, cholesterol as the sterol, dioleoyl phosphatidylethanolamine-glutaric acid as the headgroup-derivatized lipid and ET-18-OCH 3 as the ether lipid.
- the liposome's bilayer comprises about 20 mole percent of the ether lipid, about 10 mole percent of the headgroup-derivatized lipid, about 30 mole percent cholesterol and about 40 mole percent dioleoyl phosphatidylethanolamine.
- the liposome can further comprise an additional bioactive agent, that is an agent in addition to the ether lipid.
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the liposomes of this invention.
- a method of treating a mammal afflicted with a cancer including, but not limited to: a lung, brain, colon, ovarian or breast cancer.
- the method comprises administering the compositions of this invention to the mammal, in an amount containing an anticancer effective amount of the ether lipid.
- the liposome administered is a unilamellar liposome having an average diameter of from about 50 nm to about 200 nm.
- the anticancer effective amount of the etherlipid is from about 0.1 mg of the etherlipid per kg of the body weight of the mammal to about 1000 mg per kg.
- the method can also comprise administration of an additional bioactive agent, e.g., an antineoplastic agent, antimicrobial agent, therapeutic lipid or hematopoietic cell growth stimulating agent, to the mammal.
- an additional bioactive agent e.g., an antineoplastic agent, antimicrobial agent, therapeutic lipid or hematopoietic cell growth stimulating agent
- Administration of such an additional agent is typically of an effective amount of the additional agent in connection with an anticancer effective amount of the etherlipid.
- the additional agent is an anticancer agent
- either the additional agent, the etherlipid, or both can be administered in a “sub-anticancer effective amount,” that is, in an amount which may not be effective against a cancer on its own.
- a method of treating a mammal afflicted with an inflammatory disorder which comprises administering this invention's pharmaceutical composition to the mammal, in an amount containing an anti-inflammation effective amount of the etherlipid.
- an inflammatory disorder e.g., an arthritic condition, asthmatic disorder or allergic reaction
- the anti-inflammation effective amount of the etherlipid is from about 0.1 mg of the etherlipid per kg of the body weight of the mammal to about 1000 mg per kg.
- Additional bioactive agents such as additional anti-inflammatory agents, can also be administered when the liposomes of this invention are used against inflammatory disorders.
- the invention comprises a liposome having a D or L stereoisomer of an ether lipid as a component of the liposome's lipid bilayer.
- the liposomes comprising either or the two optical isomers or a racemic mixture of D and L etherlipids generally demonstrated equivalent in vitro growth inhibition against a variety of cell lines (A549, Lewis Lung, MCF7, MCF7/adr, L1210 and U-937).
- liposomes comprising the the D isomer optical isomer demonstrated a significantly significant greater activity against the L1210/vmdr line when compared to the L-isomer and the racemic mixture.
- liposomes in accordance with the invention and comprising the L stereoisomer of the ether lipid component show superior anti-cancer efficacy by significantly reducing the mean number of tumor nodules of established B16/F10 lung tumors as compared to the same liposomes comprising the D ether lipid or the ether lipid racemate.
- the L isomer formulation of liposomal etherlipid demonstrated significantly reduced toxicity compared to the D isomer liposome formulation when administered intraveneously once daily for 5 days. Both D and L isomers of the etherlipid and the racemic mxture exhibited similar hemolytic activity. This hemolytic activity was significantly attenuated by incorporation into liposomes according to the present invention.
- this invention comprises a liposome having a lipid bilayer which comprises: (a) an underivatized phosphatidylcholine; (b) a sterol; (c) a headgroup derivatized lipid containing a phosphatidylethanolamine and a moiety selected from the group consisting of dicarboxylic acids, gangliosides, polyethylene glycols and polyalkylethers, which headgroup-derivatized lipid comprises from about 5 mole percent to about 20 mole percent of the bilayer; and, (d) an etherlipid having the following formula:
- the etherlipid comprising from greater than about 10 mole percent, to less than about 30 mole percent, of the bilayer.
- “Liposomes” are self-assembling structures comprising one or more lipid bilayers, each of which surrounds an aqueous compartment and comprises two opposing monolayers of amphipathic lipid molecules.
- Amphipathic lipids comprise a polar (hydrophilic) headgroup region covalently linked to one or two non-polar (hydrophobic) acyl chains.
- Energetically unfavorable contacts between the hydrophobic acyl chains and the aqueous medium are generally believed to induce lipid molecules to rearrange such that the polar headgroups are oriented towards the aqueous medium while the acyl chains reorient towards the interior of the bilayer.
- An energetically stable structure is formed in which the acyl chains are effectively shielded from coming into contact with the aqueous medium.
- Liposomes can have a single lipid bilayer (unilamellar liposomes, “ULVs”), or multiple lipid bilayers (multilamellar liposomes, “MLVs”), and can be made by a variety of methods (for a review, see, for example, Deamer and Uster (1983)). These methods include without limitation: Bangham's methods for making multilamellar liposomes (MLVs); Lenk's, Fountain's and Cullis' methods for making MLVs with substantially equal interlamellar solute distribution (see, for example, U.S. Pat. Nos.
- ULVs can be produced from MLVs by such methods as sonication (see Paphadjopoulos et al. (1968)) or extrusion (U.S. Pat. No. 5,008,050 and U.S. Pat. No. 5,059,421).
- the etherlipid liposome of this invention can be produced by the methods of any of these disclosures, the contents of which are incorporated herein by reference.
- Liposome sizes can also be determined by a number of techniques, such as quasi-electric light scattering, and with equipment, e.g., Nicomp® particle sizers, well within the possession of ordinarily skilled artisans.
- the liposomes of this invention can be unilamellar or multilamellar.
- the liposomes are unilamellar and have diameters of less than about 200 nm, more preferably, from greater than about 50 nm to less than about 200 nm.
- Smaller liposomes are generally believed to circulate longer in mammals, which are more quickly recognized by the mammals' reticuloendothelial systems (“RES”).
- RES reticuloendothelial systems
- 200 nm liposomes for example, are generally expected to remain in circulation longer than liposomes having a 500-nm diameter. Longer circulation can enhance therapeutic efficacy by allowing more liposomes to reach their intended site of actions, e.g., tumors or inflammations.
- small liposomes i.e., those generally less than 50 nm in diameter, carry amounts of bioactive agents which may be, in some cases, too low to be of sufficient therapeutic benefit.
- R 1 of the etherlipid, the chain attached at the carbon #1 position of its glycerol backbone by way of an oxygen has the formula Y 1 Y 2 , wherein Y 2 is CH 3 or CO 2 H, but preferably is CH 3 , and Y 1 is —(CH 2 ) n1 (CH ⁇ CH) n2 (CH 2 ) n3 (CH ⁇ CH) n4 (CH 2 ) n5 (CH ⁇ CH) n6 (CH 2 ) n7 (CH ⁇ CH) n8 (CH 2 ) n9 .
- n1 is equal to zero or is an integer of from 1 to 23; n3 is equal to zero or is an integer of from 1 to 20; n5 is equal to zero or is an integer of from 1 to 17; n7 is equal to zero or is an integer of from 1 to 14; n9 is equal to zero or is an integer of from 1 to 11; and each of n2, n4, n6 and 8 is independently equal to zero or 1.
- the sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 3 to 23; that is, the chain is from 4-24 carbon atoms in length.
- the hydrocarbon chain is preferably saturated, that is, it preferably has no double bonds between adjacent carbon atoms, each of n2, n4, n6 and n8 then being equal to zero.
- R 1 is preferably (CH 2 ) n1 CH 3 . More preferably, R 1 is (CH 2 ) 17 CH 3 .
- the chain can have one or more double bonds, that is, it can be unsaturated, and one or more of n2, n4, n6 and n8 can be equal to 1.
- n2 is equal to 1
- n4 are each equal to zero
- Y 1 is (CH 2 ) n1 CH ⁇ CH(CH 2 ) n3 .
- n1 is then equal to zero or is an integer of from 1 to 21, and n3 is also zero or is an integer of from 1 to 20, at least one of n1 or n3 not being equal to zero.
- Z is oxygen, sulfur, NH, or —NHC(O)—, Z then being connected to the methyl group by way of either the nitrogen or carbonyl carbon.
- Z can also be —OC(O)—, it then being connected to the methyl group by way of either the oxygen or carbonyl carbon atom.
- Z is O; accordingly, this invention's glycerol-based etherlipids preferably have a methoxy group at the sn-2 position of their glycerol backbone.
- R 2 is an alkyl group, or a halogen-substituted alkyl group, having the formula (C(X 1 ) n10 (X 2 ) n11 ) n12 CX 3 X 4 X 5 , wherein each of X 1 , X 2 , X 3 , X 4 , and X 5 is independently hydrogen or a halogen, but is preferably hydrogen.
- n10 is equal to zero, 1 or 2; n11 is equal to zero, 1, or 2; and n12 is equal to zero or an integer of from 1 to 23, but is most preferably, zero, R 2 then being CX 3 X 4 X 5 .
- X 3 , X 4 , and X 5 are most preferably H, and R 2 then being CH 3 .
- the etherlipid preferably has a methyl group attached to its carbon #2.
- R 2 can then also be CH 2 F, CHF 2 or CF 3 .
- n12 is not zero, the sum of n10+n11 is equal to 2, n12 is preferably equal to 1, and R 2 is preferably CH 2 CH 3 , CH 2 CF 3 or CF 2 CF 3 .
- the etherlipid is one in which Y 2 is CH 3 , R 1 is (CH 2 ) n1 CH 3 , R2 is CH 3 and Z is O.
- the preferred etherlipid is therefore:
- the underivatized PC is partially or wholly unsaturated, that is, it preferably has one or two acyl chains each having at least one double bond between adjacent carbon atoms in the chain. More preferably, presently, the underivatized PC is dioleoyl phosphatidylethanolamine (“DOPE”).
- DOPE dioleoyl phosphatidylethanolamine
- sterols generally affect the fluidity of lipid bilayers (see, for example, Lewis and McElhaney (1992) and Darnell et al. (1986)) Accordingly, sterol interactions with surrounding hydrocarbon chains generally inhibit emigration of these chains from the bilayer.
- the sterol component of the bilayers of the liposomes of this invention is preferably, but not necessarily, cholesterol, and can also be a variety of other sterolic compounds.
- a “headgroup-derivatized” lipid is a lipid which, when present in a liposomal lipid bilayer with an etherlipid, can buffer the toxicity of the etherlipid. That is, the derivatized lipid can decrease the etherlipid's toxicity, such that it is generally less toxic than the free form of the etherlipid.
- Headgroup-derivatized lipids generally are amphipathic lipids comprising one or more hydrophobic acyl chains, and a phosphorylethanolamine group to which a suitable chemical moiety has been attached.
- the acyl chains typically contain from 4 to 24 carbon atoms, can be saturated or unsaturated and include palmitate and oleate chains, amongst others.
- Preferred acyl chains are those which can adopt compatible packing configurations with the hydrophobic portions of other lipids present in the bilayer, and which can interact with an etherlipid such that release of the etherlipid from the bilayer is inhibited and etherlipid toxicity is buffered.
- the headgroup derivatized lipid used herein is dipalmitoyl phosphatidylethanolamine (“DPPE”), palmitoyloleoyl phosphatidylethanolamine (“POPE”) or dioleoyl phosphatidylethanolamine (“DOPE”).
- DPPE dipalmitoyl phosphatidylethanolamine
- POPE palmitoyloleoyl phosphatidylethanolamine
- DOPE dioleoyl phosphatidylethanolamine
- Chemical moieties suitable for attachment to such lipids are those, such as dicarboxylic acids, gangliosides, polyethylene glycols, polyakyl ethers and the like, which can be attached to a phosphorylethanolamine and which give rise to lipids having toxicity buffering, circulation-enhancing properties.
- Means of identifying suitable chemical moieties, for example by subjecting derivatized lipids to in vitro and in vivo toxicity testing, are well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention.
- Means of attaching chemical moieties to polar groups are also well known to, and readily practiced by, ordinarily skilled artisans.
- Toxicity buffering capacities of headgroup-derivatized lipids can be determined by a number of in vitro and in vivo testing methods well known to, and readily practiced by, ordinarily skilled artisans, given the teachings of this invention.
- etherlipid-induced red blood cell (RBC) hemolysis can be examined in vitro by combining an etherlipid with a RBC suspension, incubating the combination, and then quantitating the percentage of RBC lysis by spectrophotometry.
- a compound's therapeutic window “TW” is derived from the relationship between the compound's induction of hemolysis and its ability to inhibit the growth of tumor cells. TW values are determined in accordance with the formula HI 5 /GI 50 (wherein “HI 5 ” equals the concentration of agent inducing the hemolysis of 5% of the red blood cells in a culture, and wherein “GI 50 ” equals the dose of an agent inducing fifty percent growth inhibition in a population of cells exposed to the agent).
- HI 5 equals the concentration of agent inducing the hemolysis of 5% of the red blood cells in a culture
- GI 50 equals the dose of an agent inducing fifty percent growth inhibition in a population of cells exposed to the agent.
- the higher its HI 5 the more therapeutically beneficial is an agent.
- lower GI 50 's indicate better therapeutic agents—a lower GI 50 value indicates that a lesser concentration of an agent is required for 50% growth inhibition. Accordingly, the higher is an agent's TW, that is the higher is its HI 5 value and the lower is its GI 50 value, the better are the agent's therapeutic properties.
- Etherlipid liposomes having bilayers comprising headgroup-derivatized lipids can have TW's of greater than 1.
- the TW of an etherlipid in a liposomal bilayer also comprising a headgroup-derivatized lipid is greater than about 1.5, more preferably, greater than about 2 and still more preferably, greater than about 3.
- Headgroup-derivatized lipids can also be circulation-enhancing lipids, that is, the modifications directed to lipid toxicity buffering can also afford circulation enhancement. Accordingly, headgroup-derivatized lipids can inhibit clearance of liposomes from the circulatory systems of animals to which they have been administered. Liposomes are generally believed to be cleared from an animal's body by way of its reticuloendothelial system (RES). Avoiding RES clearance means that the frequency of liposome administration can be reduced, and that less of a liposome-associated bioactive agent need be administered to achieve desired serum levels of the agent. Enhanced circulation times can also allow targeting of liposomes to non-RES containing tissues.
- RES reticuloendothelial system
- Liposome outer surfaces are believed to become coated with serum proteins, such as opsonins, in animals' circulatory systems. Without intending in any way to be limited by theory, it is believed that liposome clearance can be inhibited by modifying the outer surface of liposomes such that binding of serum proteins thereto is generally inhibited.
- Effective surface modification that is, alterations to the outer surfaces of liposomes which result in inhibition of opsonization and RES uptake, is believed to be accomplished by incorporating into liposomal bilayers lipids whose polar headgroups have been derivatized by attachment thereto of a chemical moiety which can inhibit the binding of serum proteins to liposomes such that the pharmacokinetic behavior of the liposomes in the circulatory systems of animals is altered (see, e.g., Blume et al. (1993); Gabizon et al. (1993); Park et al. (1992); Woodle et al. U.S. Pat. No. 5,013,556; and, U.S. Pat. No. 4,837,028).
- dicarboxylic acids such as glutaric, sebacic, succinic and tartaric acids
- headgroup-derivatized lipids are preferred components of headgroup-derivatized lipids.
- the dicarboxylic acid is glutaric acid (“GA”).
- suitable headgroup-derivatized lipids include phosphatidylethanolamine-dicarboxylic acids such as dipalmitoyl phosphatidylethanolamine-glutaric acid (“DPPE-GA”), palmitoyloleoyl phosphatidylethanolamine-glutaric acid (“POPE-GA”) and dioleoyl phosphatidylethanolamine-glutaric acid (“DOPE-GA”).
- DPPE-GA dipalmitoyl phosphatidylethanolamine-glutaric acid
- POPE-GA palmitoyloleoyl phosphatidylethanolamine-glutaric acid
- DOPE-GA dioleoyl phosphatidylethanol
- the derivatized lipid is DOPE-GA.
- the headgroup-derivatized can comprise from about 5 mole percent to about 50 mole percent of the liposome's lipid bilayer, but most preferably comprises about 10 mole percent of the bilayer.
- the liposomes of this invention can comprise one or more additional lipids, that is, lipids in addition to the sterol, underivatized PE, headgroup-derivatized lipid and etherlipid already present in the liposomes' bilayers. Additional lipids are selected for their ability to adapt compatible packing conformations with the other lipid components of the bilayer such that the lipid constituents are tightly packed and release of the lipids from the bilayer is inhibited. Lipid-based factors contributing to compatible packing conformations are well known to ordinarily skilled artisans and include, without limitation, acyl chain length and degree of unsaturation, as well as the headgroup size and charge.
- PC's phosphatidylcholines
- EPC egg phosphatidylcholine
- DOPC dioleoyl phosphatidylcholine
- Preferred embodiments of this invention have the underivatized PE being DOPE, the sterol being cholesterol (“chol”), the etherlipid being ET-18-OCH3 and the headgroup-derivatized lipid being DOPE-GA.
- the liposome comprises DOPE, chol, ET-18-O—CH 3 in a respective molar ratio of 4:3:1:2, wherein DOPE comprises 40 mole % of the liposomes' bilayers, chol 30% mole, DOPE-GA 10 mole % and the etherlipid 20 mole %.
- the liposomes are unilamellar and have an average diameter of from about 50 nm to about 200 nm, “average” meaning that the median diameter of a population of this invention's liposomes is between 50 and 200 nm.
- the liposome can comprise an additional bioactive agent, that is, a bioactive agent in addition to the etherlipid.
- a “bioactive agent” is any compound or composition of matter that can be administered to animals, preferably humans. Such agents can have biological activity in animals; the agents can also be used diagnostically in the animals.
- Bioactive agents which may be associated with liposomes include, but are not limited to: antiviral agents such as acyclovir, zidovudine and the interferons; antibacterial agents such as aminoglycosides, cephalosporins and tetracyclines; antifungal agents such as polyene antibiotics, imidazoles and triazoles; antimetabolic agents such as folic acid, and purine and pyrimidine analogs; antineoplastic agents such as the anthracycline antibiotics and plant alkaloids; sterols such as cholesterol; carbohydrates, e.g., sugars and starches; amino acids, peptides, proteins such as cell receptor proteins, immunoglobulins, enzymes, hormones, neurotransmitters and glycoproteins; dyes; radiolabels such as radioisotopes and radioisotope-labelled compounds; radiopaque compounds; fluorescent compounds; mydriatic compounds; bronchodilators; local anesthetics; and the like
- Liposomal bioactive agent formulations can enhance the therapeutic index of the bioactive agent, for example by buffering the agent's toxicity. Liposomes can also reduce the rate at which a bioactive agent is cleared from the circulation of animals. Accordingly, liposomal formulation of bioactive agents can mean that less of the agent need be administered to achieve the desired effect.
- Additional bioactive agents preferred for the liposome of this invention include antimicrobial, anti-inflammatory and antineoplastic agents, or therapeutic lipids, for example, ceramides. Most preferably, the additional bioactive agent is an antineoplastic agent.
- Liposomes can be loaded with one or more biologically active agents by solubilizing the agent in the lipid or aqueous phase used to prepare the liposomes.
- ionizable bioactive agents can be loaded into liposomes by first forming the liposomes, establishing an electrochemical potential, e.g., by way of a pH gradient, across the outermost liposomal bilayer, and then adding the ionizable agent to the aqueous medium external to the liposome (see Bally et al. U.S. Pat. No. 5,077,056 and WO86/01102).
- the liposome of this invention can be dehydrated, stored and then reconstituted such that a substantial portion of its internal contents are retained.
- Liposomal dehydration generally requires use of a hydrophilic drying protectant such as a disaccharide sugar at both the inside and outside surfaces of the liposome bilayers (see U.S. Pat. No. 4,880,635).
- This hydrophilic compound is generally believed to prevent the rearrangement of the lipids in the liposome, so that the size and contents are maintained during the drying procedure and through subsequent rehydration.
- Appropriate qualities for such drying protectants are that they be strong hydrogen bond acceptors, and possess stereochemical features that preserve the intramolecular spacing of the liposome bilayer components.
- the drying protectant can be omitted if the liposome preparation is not frozen prior to dehydration, and sufficient water remains in the preparation subsequent to dehydration.
- composition comprising a pharmaceutically acceptable carrier and the liposome of this invention.
- “Pharmaceutically acceptable carriers” as used herein are those media generally acceptable for use in connection with the administration of lipids and liposomes, including liposomal bioactive agent formulations, to animals, including humans.
- compositions are generally formulated according to a number of factors well within the purview of the ordinarily skilled artisan to determine and account for, including without limitation: the particular liposomal bioactive agent used, its concentration, stability and intended bioavailability; the disease, disorder or condition being treated with the liposomal composition; the subject, its age, size and general condition; and the composition's intended route of administration, e.g., nasal, oral, ophthalmic, topical, transdermal, vaginal, subcutaneous, intramammary, intraperitoneal, intravenous, or intramuscular (see, for example, Nairn (1985)).
- Typical pharmaceutically acceptable carriers used in parenteral bioactive agent administration include, for example, D5W, an aqueous solution containing 5% weight by volume of dextrose, and physiological saline.
- Pharmaceutically acceptable carriers can contain additional ingredients, for example those which enhance the stability of the active ingredients included, such as preservatives and anti-oxidants.
- a method of treating a mammal afflicted with a cancer which comprises administering the pharmaceutical composition of this invention to the mammal, etherlipids being believed to be selectively cytotoxic to tumor cells.
- a cancer e.g., a brain, breast, lung, colon or ovarian cancer, or a leukemia, lymphoma, sarcoma, carcinoma
- etherlipids being believed to be selectively cytotoxic to tumor cells.
- liposomal etherlipids can be used to treat cancers treated with free, that is, nonliposomal, etherlipids.
- encapsulation of an etherlipid in a liposome can enhance its therapeutic index, and therefore make the liposomal etherlipid a more effective treatment.
- an amount of the composition comprising an anticancer effective amount of the etherlipid is administered, preferably intravenously.
- anticancer effective amounts are amounts effective to inhibit, ameliorate, lessen or prevent establishment, growth, metastasis or invasion of one or more cancers in animals to which the etherlipids have been administered.
- Anddticancer effective amounts are generally chosen in accordance with a number of factors, e.g., the age, size and general condition of the subject, the cancer being treated and the intended route of administration, and determined by a variety of means, for example, dose ranging trials, well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention.
- Antineoplastic effective amounts of the liposomal etherlipid of this invention are about the same as such amounts of free, nonliposomal, etherlipids.
- the liposome administered is a unilamellar liposome having an average diameter of from about 50 nm to about 200 nm.
- the anti-cancer treatment method can include administration of one or more bioactive agents in addition to the liposomal etherlipid, these additional agents preferably, but not necessarily, being included in the same liposome as the etherlipid.
- the additional bioactive agents which can be entrapped in liposomes' internal compartments or sequestered in their lipid bilayers, are preferably, but not necessarily, anticancer agents or cellular growth promoting factors.
- This invention also provides a method of treating a mammal afflicted with an antiinflammatory disorder, e.g., arthritic conditions, asthmatic disorders and allergic reactions, comprising administering to the mammal an amount of the pharmaceutical composition provided herein sufficient to contain an anti-inflammation effective amount of the liposomal etherlipid.
- Inflammation is a process of cytological and histological reactions occurring in affected blood vessels, and surrounding tissues, in response to an injury (see, e.g., Stedman's Medical Dictionary ( Illustrated ) (1982)). Inflammatory responses to such stimuli include local reactions and resulting morphological changes, destruction or removal of injurious materials and activation of repair mechanisms. Thus, inflammation can be part of the process by which animals heal themselves.
- inflammation can also occur in response to abnormal physiological stimuli, and can cause problems in the body.
- Joints for example, become inflamed in arthritic conditions such as gout, filary arthritis, rheumatoid arthritis and Lyme disease (see, e.g., Stedman's Medical Dictionary ( Illustrated ), supra at pages 123-124).
- arthritic conditions such as gout, filary arthritis, rheumatoid arthritis and Lyme disease (see, e.g., Stedman's Medical Dictionary ( Illustrated ), supra at pages 123-124).
- These states may be characterized by the extravasation of cells, i.e, the egress of cells from the circulation into the inflamed area.
- Agents which can inhibit such extravasation, or which can otherwise inhibit inflammatory responses to abnormal physiological stimuli can be used to ameliorate the inflammation.
- an “anti-inflammation effective amount” of a liposomal etherlipid typically from about 0.1 mg to about 1000 mg per kg of a treated mammal's body weight, is any amount of the etherlipid effective to ameliorate, inhibit or prevent inflammatory responses or reactions in animals afflicted with conditions characterized by abnormal inflammation, i.e., inflammation which is in response to abnormal physiological stimuli and which is not part of the body's normal repair processes in response to an injury.
- D and L etherlipid stereoisomers can be prepared in small quantities by techniques well known to those of ordinary skill in the art. These methods have been utilized to prepare L etherlipid. However, sufficient quantities of the D etherlipid of sufficient purity for in vitro and in vivo experiments were not commercially available. Non-limiting exemplary techniques are described in Examples 1 and 2.
- the next step involves reacting the n-Octadecylmesylate with 2,3-Isopropylidene-sn-glycerol, followed by hydrolysis to give 1-O-Octadecyl-sn-glycerol.
- the 1-O-Octadecyl-sn-glycerol is purified by crystallization, washed and dried.
- the 1-O-Octadecyl-sn-glycerol is reacted with triphenylmethylchloride (tritylchloride).
- the reaction mixture in this step is worked up and concentrated.
- the 1-O-Octadecyl-3-O-trityl-sn-glycerol product is crystallized and washed.
- the 1-O-Octadecyl-3-O-trityl-sn-glycerol is reacted with Methyliodide to form a 1-O-Octadecyl-2-O-methyl-3-O-trityl-sn-glycerol product.
- the trityl group is hydrolyzed to give 1-O-Octadecyl-2-O-methyl-sn-glycerol, which is subsequently purified by chromatography and crystallization.
- n-Octadecylalcohol is reacted with Mesylchloride to form n-Octadecylmesylate.
- the mother liquor is concentrated until a solid residue is obtained. This residue is purified by crystallization and washed.
- the second step involves reacting the n-Octadecylmesylate with 1,2-Isopropylidene-sn-glycerol, followed by hydrolysis to give 1-O-Octadecyl-sn-glycerol.
- the 1-O-Octadecyl-sn-glycerol is purified by crystallization, washed and dried.
- the third step involves reacting 1-O-Octadecyl-sn-glycerol with triphenylmethylchloride (tritylchloride).
- the reaction mixture in this step is worked up and concentrated.
- the 1-O-Octadecyl-3-O-trityl-sn-glycerol product is crystallized and washed.
- the fourth step involves reacting the 1-O-Octadecyl-3-O-trityl-sn-glycerol with Methyliodide to form a 1-O-Octadecyl-2-O-methyl-3-O-trityl-sn-glycerol product. After crystallyzation of the product, the trityl group is hydrolyzed to give 1-O-Octadecyl-2-O-methyl-sn-glycerol, which is subsequently purified by chromatography and crystallization.
- the fifth step involves reacting 1-O-Octadecyl-2-O-methyl-sn-glycerol with Phosphorus oxychloride and then with Choline tosylate to form the crude Ether Lipid.
- the reaction mixture is worked up and concentrated under vacuum.
- the crude Ether Lipid is obtained by crystallization, centrifugation and washing.
- Liposomal formulations in accordance with the invention were prepared and evaluated as described in the following examples.
- Liposomal formulations were prepared as described in U.S. Pat. No. 5,762,958, incorporated herein by reference.
- Venous blood was collected using 3.8% sodium citrate in a Vacutainer. Dilution ratio is 1 to 9 (citrate solution: blood). The effect of D and L etherlipid and liiposmes containing them on aggregation of platelets from rats, dogs, monkeys and humans was tested.
- Platelet aggregation response was determined by increased resistance using an impedance electrode in a platelet suspension. Resistance measurements were taken 6-8 minutes after addition of the test article to 1 ml whole blood or platelet rich plasma (PRP). The results of the evaluations are reported in Table 1. TABLE 1 Platelet Aggregation Response in Whole Blood Dog Blood Rat Blood Human Blood Response Response Response Treatment Concentration ( ⁇ ) ( ⁇ ) ( ⁇ ) L-ELL 100 ⁇ M 8.5 0 0 D-ELL 100 ⁇ M 0 0 0 PAF 0.05 ⁇ M 14.8 0 6.0 ADP 20 ⁇ M 4.0 2.0 6.3 collagen 20 ⁇ g/ ⁇ L 12 34.1 36
- mice were weighed and observed twice weekly and mortality was recorded daily. Experiments were terminated 30 days after the treatment. The results are reported in Tables 3.
- L and D isomers of ET-18-OCH3 formulated in ELL-12 differed in vivo when adminsitered intraveneously. L-ELL-12 exhibited less acute toxicity than D-ELL-12 when administered i.V.
- TABLE 3 Toxicity of Stereoisomeric Ether Lipid Liposomal Formulations on C57/BL6 Mice Dose Number of Survivors/Total Mice per Group mg/kg ELL-12(L) ELL-12(D) i.v. x 1 150 3/3 3/3 200 1/3 0/3 iv. x 5 daily 50 5/5 5/5 75 5/5 0/5 100 1/5 0/5
- the anti-tumor activities of the D and L etherlipid were evaluated against A549, a human non-small cell lung carcinoma cell line; MCF 7, a human breast carcinoma line and MCF 7/adr, multi-drug resistant human breast carcinoma; were obtained from the DCT Tumor Repository (NCI-Frederick Cancer Research Facility, Frederick, Md.).
- U-937 a human histiocytic lymphoma cell line, was obtained from the American Type Culture Collection. Stock cultures of these human cell lines were maintained in RPMI 1640 tissue culture media (Life Technologies, Gaithersburg, Md.) supplemented with 10% heat inactivated fetal bovine serum (Life Technologies) and 10 mM HEPES (Life Technologies).
- L1210 and L1210/vmdr murine lymphocytic leukemias, (Yale University School of Medicine).
- L1210/vmdr a selected line of L1210, was transfected with a plasmid (pHaMDR1/A) containing the mdr I gene.
- SRB Sulforhodamine B
- GI 50 the concentration of drug which inhibits cell growth 50%.
- the detailed methodology of the SRB assay is described elsewhere (2,3). Briefly, 96-well microtiter plates were inoculated with 100 ul of the above cell lines at optimal cell densities, 3500-15,000 cells/well, in medium (RPMI 1640 with L-glutamine (Mediatech, Herndon, Va.)) supplemented with 10% fetal bovine serum (Life Technologies) for all cell lines. The plates were then incubated for 24 hours at 37° C., 100% humidity, and 5% CO 2 .
- dose response curves were generated and the GI 50 values were calculated. The GI 50 values for each experiment were calculated using data obtained from three duplicate wells on two separate plates. The mean GI 50 values and standard deviations were then calculated from the GI 50 's from each independent experiment.
- FIG. 3 demonstrates that D and L ELL-12 administered i.p. were equally effective against P388 leukemia.
- ELL-12 LI or D
- FIG. 4 demonstrates that the L isomer liposome formulation, when administered against established B16/F10 lung tumors, significantly (p ⁇ 0.05) reduced the mean number of tumor nodules when compared to control or the D isomer liposome formulation.
- Hemolytic Activity Hemolysis was assessed using washed red blood cells from Fisher rats that were adjusted to a cell density of 1 ⁇ 10 8 cells/ml. Samples were incubated at 37° C. for 30 minutes and certrifuged to pellet cells. Absorbances for the supernatants were measured at 550 nm and the results were expressed as percent hemolysis elicited by 1 mg/ml of ether lipid standard.
- RNAase DNAase free
- RNAase DNAase free
- Propidium iodide 100 ⁇ l of a 1 mg/ml stock
- CD11b-PE Monoclonal CD11b-PE was purchased from Ancell (Bayport, Minn.) and CD71-FITC and CD82-PE were purchased from Pharmingen (San Diego, Calif.). Monclonal IgG1 PE- or FITC-conjugated raised against trinitrophenol were used as iso-type controls to assess any nonspecific binding.
- U-937 (human histiocytic lyphoma) cells from ATCC (Manassas, Va.) were harvested and centrifuged at 1000 rpm, 4° C., and washed twice in Dulbecco's PBS without Mg2+ or Ca2+ (DPBS, from Life Technologies) supplemented with 0.1% sodium azide (Sigma Chemicals) and 1% heat inactivated fetal bovine serum (washing buffer). 1 ⁇ 10 6 cells were aliquoted into Eppendorf tubes to a total volume of 100 ⁇ l in cell staining buffer (PBS without Mg or Ca, supplemented with 0.1% sodium azide, 1% heat inactivated fetal bovine serum and 5% mouse serum).
- conjugated monoclonal antibody or conjugated iso-type control antibody was added to 1 ⁇ 10 6 cells (2.5 ⁇ l of CD11b or 20 ⁇ l of CD71 or CD82 were used according to the protocol supplied by the manufacturer), and the samples were incubated on ice, in the dark, for 60 min. Cells were then washed twice with washing buffer, fixed in 4% p-formaldehyde in PBS for 10 min, resuspended in washing buffer and analyzed by FACScan.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.
Description
- The invention relates to a liposome comprising an ether lipid stereoisomer in the lipid bilayer of the liposome. The invention also encompasses pharmaceutical compositions comprising the liposome and methods of treating an animal with the liposome.
- Pharmaceutical therapeutics useful in the treatment of cancers or inflammatory conditions generally aim to slow the growth of, or destroy cancer cells or modulate the cells responsible for inflammatory responses. Optimal therapeutics, for instance cancer chemotherapy provides the decrease or eradication of cancer cell growth while avoiding or diminishing collateral damage to normal cells and tissues. The most effective anticancer agents are able to selectively target cancer cells while leaving normal cells relatively unaffected. Some etherlipids have been shown to be effective anticancer agents. However, the use of most etherlipids in vivo (to treat animals) has been accompanied by certain levels of toxicity to normal cells. Etherlipids are amphipathic lipids with ether linkages connecting their hydrocarbons with their molecular backbones. They are synthetic analogs of platelet activating factor (“PAF”; 1-O-2-acetyl-sn-glycero-3-phosphocholine). PAF is an effector believed to be involved in a variety of physiological processes, such as inflammation, immune responses and allergic reactions.
- Ether lipids can accumulate in cell membranes, following which the lipids may affect the cells in a number of ways. Cell membrane accumulation can lead to disturbance of membrane lipid organization by a detergent-like activity of ether lipids; membrane structure, and hence, cell stability, can be disrupted by this activity. Phospholipid metabolism can also be disrupted, as the activities of several of the enzymes involved, e.g., CTP:phosphocholine cytidyl transferase, diacylglycerol kinase, sodium/potassium adenosine triphosphate phosphatase, acyl transferases, lysophospholipase, and phospholipases C and D, are inhibited in the presence of ether lipids. Ether lipids can also affect transmembrane signaling pathways, nutrient uptake, cellular differentiation and apoptosis.
- Moreover, ether lipids are believed to be cytotoxic to cancer cells, and have been shown to be effective anticancer agents in animals (see, for example, Lohmeyer and Bittman, 1994; Lu et al. (1994a); Lu et al. (1994b); Dietzfelbinger et al. (1993); Zeisig et al. (1993); Berdel (1991); Workman (1991); Workman et al. (1991); Bazill and Dexter (1990); Berdel (1990); Guivisdalsky et al. (1990a); Guivisdalsky et al. (1990b); Powis et al. (1990); Layton et al. (1980); Great Britain Patent No. 1,583,661; U.S. Pat. No. 3,752,886). However, ether lipids are generally not toxic to most normal cells. Ether lipids' ability to act selectively on cancer cells is believed to be due to the cancer cells' lack of the alkyl cleavage enzymes necessary for hydrolysis of the lipids; the resulting intracellular lipid accumulation can disrupt the cells' functioning in a variety of ways. Normal cells typically possess these enzymes, and hence, are able to prevent the intracellular accumulation of ether lipids.
- However, not all normal cells contain sufficient levels of alkyl cleavage enzymes to prevent intracellular ether lipid accumulation. Cells which do not possess the requisite levels of the enzymes can be subject to the same disruptive effects of ether lipid action as are cancer cells. Red blood cells, for example, lack the requisite alkyl cleavage enzymes, and hence, are also subject to a detergent-like activity of ether lipids. Hemolysis which results from exposure of these cells to ether lipids having detergent-like activity can be a major drawback to therapeutic use of the ether lipids (see, for example, Houlihan et al., 1995).
- A number of different approaches are potentially available for decreasing or eliminating such drug-induced toxicity. One such approach is to incorporate the drugs into lipid-based carriers, e.g., liposomes. Such carriers can buffer drug toxicity, for example, by sequestering the drug in the carrier such that the drug is unavailable for inducing toxicity. Lipid carriers can also buffer drug-induced toxicity by interacting with the drug such that the drug is then itself unable to interact with the cellular targets through which it exerts its cytotoxic effects. The carriers also maintain the ability of the drugs to be therapeutically effective when released therefrom, e.g., when the carriers are broken down in the vicinity of tumors.
- U.S. Pat. No. 5,762,958, incorporated herein by reference, describes a liposome having an ether lipid as a component of the liposome's lipid bilayer. Such liposomes reduce the toxicity of the ether lipids without inhibiting their anti-cancer efficacy. Nevertheless, there is no suggestion in U.S. Pat. No. 5,762,958 that the chirality of the ether lipid would have any effect on the toxicity of the liposomal formulation.
- This invention provides a liposome having a lipid bilayer which comprises: an ether lipid having either a D or L chirality. Preferably, the lipid bilayer of the liposome comprises at least one lipid in addition to the D or L etherlipid. Most preferably, the liposome comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine (also referred to herein as the “headgroup-derivatized lipid”), and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. Preferably, the ether lipid has the following formula:
- wherein Y1 is (CH2)n1(CH═CH)n2(CH2)n3(CH═CH)n4(CH2)n5(CH═CH)n6(CH2)n7(CH═CH)n8(CH2)n9. The sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 3 to 23, n1 is zero or an integer of from 1 to 22, n3 is zero or an integer of from 1 to 19, n5 is zero or an integer of from 1 to 16, n7 is zero or an integer of from zero to 16, n9 is zero or an integer of from 1 to 10, and each of n2, n4, n6 and 8 is independently zero or 1. Y2 is CH3 or CO2H.
- Z is oxygen or sulfur. Preferably, Z is 0; accordingly, this invention's glycerol-based etherlipids preferably have a methoxy group at the sn-2 position of their glycerol backbone.
-
- also known as “ET-18-OCH3,” or “edelfosine”).
- Preferably, the liposome is a unilamellar liposome having a diameter of from greater than about 50 nm to less than about 200 nm, the underivatized phosphatidylcholine is an unsaturated or partially unsaturated phosphatidylcholine, more preferably, dioleoyl phosphatidylcholine, and the sterol is cholesterol. The headgroup derivatized lipid preferably comprises a phosphatidylethanolamine (“PE”) selected from the group consisting of dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and dioleoyl phosphatidylethanolamine, and a dicarboxylic acid selected from the group consisting of glutaric acid, sebacic acid, succinic acid and tartaric acid. More preferably, the PE is dioleoyl phosphatidylethanolamine and the dicarboxylic acid is glutaric acid.
- Preferred embodiments of this invention's liposome have bilayers containing dioleoyl phosphatidylcholine as the underivatized PC, cholesterol as the sterol, dioleoyl phosphatidylethanolamine-glutaric acid as the headgroup-derivatized lipid and ET-18-OCH3 as the ether lipid. Most preferably, presently, the liposome's bilayer comprises about 20 mole percent of the ether lipid, about 10 mole percent of the headgroup-derivatized lipid, about 30 mole percent cholesterol and about 40 mole percent dioleoyl phosphatidylethanolamine. The liposome can further comprise an additional bioactive agent, that is an agent in addition to the ether lipid.
- Also provided herein is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the liposomes of this invention. Further provided is a method of treating a mammal afflicted with a cancer, including, but not limited to: a lung, brain, colon, ovarian or breast cancer. The method comprises administering the compositions of this invention to the mammal, in an amount containing an anticancer effective amount of the ether lipid. Preferably, the liposome administered is a unilamellar liposome having an average diameter of from about 50 nm to about 200 nm. Typically, the anticancer effective amount of the etherlipid is from about 0.1 mg of the etherlipid per kg of the body weight of the mammal to about 1000 mg per kg.
- The method can also comprise administration of an additional bioactive agent, e.g., an antineoplastic agent, antimicrobial agent, therapeutic lipid or hematopoietic cell growth stimulating agent, to the mammal. Administration of such an additional agent is typically of an effective amount of the additional agent in connection with an anticancer effective amount of the etherlipid. However, when the additional agent is an anticancer agent, either the additional agent, the etherlipid, or both can be administered in a “sub-anticancer effective amount,” that is, in an amount which may not be effective against a cancer on its own.
- Still further provided herein is a method of treating a mammal afflicted with an inflammatory disorder, e.g., an arthritic condition, asthmatic disorder or allergic reaction, which comprises administering this invention's pharmaceutical composition to the mammal, in an amount containing an anti-inflammation effective amount of the etherlipid. Typically, the anti-inflammation effective amount of the etherlipid is from about 0.1 mg of the etherlipid per kg of the body weight of the mammal to about 1000 mg per kg. Additional bioactive agents, such as additional anti-inflammatory agents, can also be administered when the liposomes of this invention are used against inflammatory disorders.
- Other than its critical stereoisomeric aspects, individual elements of the invention and their importance are described in detail in U.S. Pat. No. 5,762,958, incorporated herein by reference. The invention comprises a liposome having a D or L stereoisomer of an ether lipid as a component of the liposome's lipid bilayer. The liposomes comprising either or the two optical isomers or a racemic mixture of D and L etherlipids generally demonstrated equivalent in vitro growth inhibition against a variety of cell lines (A549, Lewis Lung, MCF7, MCF7/adr, L1210 and U-937). However, liposomes comprising the the D isomer optical isomer demonstrated a significantly significant greater activity against the L1210/vmdr line when compared to the L-isomer and the racemic mixture. However, in vivo, liposomes in accordance with the invention and comprising the L stereoisomer of the ether lipid component show superior anti-cancer efficacy by significantly reducing the mean number of tumor nodules of established B16/F10 lung tumors as compared to the same liposomes comprising the D ether lipid or the ether lipid racemate. Additionally, the L isomer formulation of liposomal etherlipid demonstrated significantly reduced toxicity compared to the D isomer liposome formulation when administered intraveneously once daily for 5 days. Both D and L isomers of the etherlipid and the racemic mxture exhibited similar hemolytic activity. This hemolytic activity was significantly attenuated by incorporation into liposomes according to the present invention.
- Preferably, this invention comprises a liposome having a lipid bilayer which comprises: (a) an underivatized phosphatidylcholine; (b) a sterol; (c) a headgroup derivatized lipid containing a phosphatidylethanolamine and a moiety selected from the group consisting of dicarboxylic acids, gangliosides, polyethylene glycols and polyalkylethers, which headgroup-derivatized lipid comprises from about 5 mole percent to about 20 mole percent of the bilayer; and, (d) an etherlipid having the following formula:
- the etherlipid comprising from greater than about 10 mole percent, to less than about 30 mole percent, of the bilayer.
- “Liposomes” are self-assembling structures comprising one or more lipid bilayers, each of which surrounds an aqueous compartment and comprises two opposing monolayers of amphipathic lipid molecules. Amphipathic lipids comprise a polar (hydrophilic) headgroup region covalently linked to one or two non-polar (hydrophobic) acyl chains. Energetically unfavorable contacts between the hydrophobic acyl chains and the aqueous medium are generally believed to induce lipid molecules to rearrange such that the polar headgroups are oriented towards the aqueous medium while the acyl chains reorient towards the interior of the bilayer. An energetically stable structure is formed in which the acyl chains are effectively shielded from coming into contact with the aqueous medium.
- Liposomes can have a single lipid bilayer (unilamellar liposomes, “ULVs”), or multiple lipid bilayers (multilamellar liposomes, “MLVs”), and can be made by a variety of methods (for a review, see, for example, Deamer and Uster (1983)). These methods include without limitation: Bangham's methods for making multilamellar liposomes (MLVs); Lenk's, Fountain's and Cullis' methods for making MLVs with substantially equal interlamellar solute distribution (see, for example, U.S. Pat. Nos. 4,522,803, 4,588,578, 5,030,453, 5,169,637 and 4,975,282); and Paphadjopoulos et al.'s reverse-phase evaporation method (U.S. Pat. No. 4,235,871) for preparing oligolamellar liposomes. ULVs can be produced from MLVs by such methods as sonication (see Paphadjopoulos et al. (1968)) or extrusion (U.S. Pat. No. 5,008,050 and U.S. Pat. No. 5,059,421). The etherlipid liposome of this invention can be produced by the methods of any of these disclosures, the contents of which are incorporated herein by reference.
- Various methodologies, such as sonication, homogenization, French Press application and milling can be used to prepare liposomes of a smaller size from larger liposomes. Extrusion (see U.S. Pat. No. 5,008,050) can be used to size reduce liposomes, that is to produce liposomes having a predetermined mean size by forcing the liposomes, under pressure, through filter pores of a defined, selected size. Tangential flow filtration (see WO89/008846), can also be used to regularize the size of liposomes, that is, to produce liposomes having a population of liposomes having less size heterogeneity, and a more homogeneous, defined size distribution. The contents of these documents are incorporated herein by reference. Liposome sizes can also be determined by a number of techniques, such as quasi-electric light scattering, and with equipment, e.g., Nicomp® particle sizers, well within the possession of ordinarily skilled artisans.
- The liposomes of this invention can be unilamellar or multilamellar. Preferably the liposomes are unilamellar and have diameters of less than about 200 nm, more preferably, from greater than about 50 nm to less than about 200 nm. Smaller liposomes are generally believed to circulate longer in mammals, which are more quickly recognized by the mammals' reticuloendothelial systems (“RES”). Thus, 200 nm liposomes, for example, are generally expected to remain in circulation longer than liposomes having a 500-nm diameter. Longer circulation can enhance therapeutic efficacy by allowing more liposomes to reach their intended site of actions, e.g., tumors or inflammations. However, small liposomes, i.e., those generally less than 50 nm in diameter, carry amounts of bioactive agents which may be, in some cases, too low to be of sufficient therapeutic benefit.
- R1 of the etherlipid, the chain attached at the
carbon # 1 position of its glycerol backbone by way of an oxygen, has the formula Y1Y2, wherein Y2 is CH3 or CO2H, but preferably is CH3, and Y1 is —(CH2)n1(CH═CH)n2(CH2)n3(CH═CH)n4(CH2)n5(CH═CH)n6(CH2)n7(CH═CH)n8(CH2)n9. n1 is equal to zero or is an integer of from 1 to 23; n3 is equal to zero or is an integer of from 1 to 20; n5 is equal to zero or is an integer of from 1 to 17; n7 is equal to zero or is an integer of from 1 to 14; n9 is equal to zero or is an integer of from 1 to 11; and each of n2, n4, n6 and 8 is independently equal to zero or 1. The sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 3 to 23; that is, the chain is from 4-24 carbon atoms in length. - The hydrocarbon chain is preferably saturated, that is, it preferably has no double bonds between adjacent carbon atoms, each of n2, n4, n6 and n8 then being equal to zero. Accordingly, R1 is preferably (CH2)n1CH3. More preferably, R1 is (CH2)17CH3. Alternatively, the chain can have one or more double bonds, that is, it can be unsaturated, and one or more of n2, n4, n6 and n8 can be equal to 1. For example, when the unsaturated hydrocarbon has one double bond, n2 is equal to 1, n4, n6 and n8 are each equal to zero and Y1 is (CH2)n1CH═CH(CH2)n3. n1 is then equal to zero or is an integer of from 1 to 21, and n3 is also zero or is an integer of from 1 to 20, at least one of n1 or n3 not being equal to zero.
- Z is oxygen, sulfur, NH, or —NHC(O)—, Z then being connected to the methyl group by way of either the nitrogen or carbonyl carbon. Z can also be —OC(O)—, it then being connected to the methyl group by way of either the oxygen or carbonyl carbon atom. Preferably, Z is O; accordingly, this invention's glycerol-based etherlipids preferably have a methoxy group at the sn-2 position of their glycerol backbone.
- R2 is an alkyl group, or a halogen-substituted alkyl group, having the formula (C(X1)n10(X2)n11)n12CX3X4X5, wherein each of X1, X2, X3, X4, and X5 is independently hydrogen or a halogen, but is preferably hydrogen. n10 is equal to zero, 1 or 2; n11 is equal to zero, 1, or 2; and n12 is equal to zero or an integer of from 1 to 23, but is most preferably, zero, R2 then being CX3X4X5. X3, X4, and X5 are most preferably H, and R2 then being CH3. Accordingly, the etherlipid preferably has a methyl group attached to its
carbon # 2. However, R2 can then also be CH2F, CHF2 or CF3. When n12 is not zero, the sum of n10+n11 is equal to 2, n12 is preferably equal to 1, and R2 is preferably CH2CH3, CH2CF3 or CF2CF3. -
- that is, 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (“ET-18-OCH3” or “edelfosine”).
- Preferably, the underivatized PC is partially or wholly unsaturated, that is, it preferably has one or two acyl chains each having at least one double bond between adjacent carbon atoms in the chain. More preferably, presently, the underivatized PC is dioleoyl phosphatidylethanolamine (“DOPE”).
- “Sterols” generally affect the fluidity of lipid bilayers (see, for example, Lewis and McElhaney (1992) and Darnell et al. (1986)) Accordingly, sterol interactions with surrounding hydrocarbon chains generally inhibit emigration of these chains from the bilayer. The sterol component of the bilayers of the liposomes of this invention is preferably, but not necessarily, cholesterol, and can also be a variety of other sterolic compounds.
- A “headgroup-derivatized” lipid is a lipid which, when present in a liposomal lipid bilayer with an etherlipid, can buffer the toxicity of the etherlipid. That is, the derivatized lipid can decrease the etherlipid's toxicity, such that it is generally less toxic than the free form of the etherlipid. Headgroup-derivatized lipids generally are amphipathic lipids comprising one or more hydrophobic acyl chains, and a phosphorylethanolamine group to which a suitable chemical moiety has been attached. The acyl chains typically contain from 4 to 24 carbon atoms, can be saturated or unsaturated and include palmitate and oleate chains, amongst others.
- Preferred acyl chains are those which can adopt compatible packing configurations with the hydrophobic portions of other lipids present in the bilayer, and which can interact with an etherlipid such that release of the etherlipid from the bilayer is inhibited and etherlipid toxicity is buffered. More preferably, the headgroup derivatized lipid used herein is dipalmitoyl phosphatidylethanolamine (“DPPE”), palmitoyloleoyl phosphatidylethanolamine (“POPE”) or dioleoyl phosphatidylethanolamine (“DOPE”). Most preferably, presently, the lipid is DOPE.
- Chemical moieties suitable for attachment to such lipids are those, such as dicarboxylic acids, gangliosides, polyethylene glycols, polyakyl ethers and the like, which can be attached to a phosphorylethanolamine and which give rise to lipids having toxicity buffering, circulation-enhancing properties. Means of identifying suitable chemical moieties, for example by subjecting derivatized lipids to in vitro and in vivo toxicity testing, are well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention. Means of attaching chemical moieties to polar groups are also well known to, and readily practiced by, ordinarily skilled artisans.
- Toxicity buffering capacities of headgroup-derivatized lipids can be determined by a number of in vitro and in vivo testing methods well known to, and readily practiced by, ordinarily skilled artisans, given the teachings of this invention. For example, etherlipid-induced red blood cell (RBC) hemolysis can be examined in vitro by combining an etherlipid with a RBC suspension, incubating the combination, and then quantitating the percentage of RBC lysis by spectrophotometry.
- A compound's therapeutic window “TW” is derived from the relationship between the compound's induction of hemolysis and its ability to inhibit the growth of tumor cells. TW values are determined in accordance with the formula HI5/GI50 (wherein “HI5” equals the concentration of agent inducing the hemolysis of 5% of the red blood cells in a culture, and wherein “GI50” equals the dose of an agent inducing fifty percent growth inhibition in a population of cells exposed to the agent). The higher an agent's HI5 value, the less hemolytic is the agent; as HI5's increase, an agent is required to be present in greater concentration in order to induce 5% hemolysis than would be the case if the agent's HI5 value was lower. Hence, the higher its HI5, the more therapeutically benefical is an agent. By contrast, lower GI50's indicate better therapeutic agents—a lower GI50 value indicates that a lesser concentration of an agent is required for 50% growth inhibition. Accordingly, the higher is an agent's TW, that is the higher is its HI5 value and the lower is its GI50 value, the better are the agent's therapeutic properties.
- Generally, when a bioactive agent's TW is less than 1, the agent cannot be used effectively. That is, the agent's HI5 value is sufficiently low, and its GI50 value sufficiently high, that it is generally not possible to administer enough of the agent to achieve a sufficient level of tumor growth inhibition without also attaining an unacceptable level of hemolysis. Etherlipid liposomes having bilayers comprising headgroup-derivatized lipids can have TW's of greater than 1. Preferably, the TW of an etherlipid in a liposomal bilayer also comprising a headgroup-derivatized lipid is greater than about 1.5, more preferably, greater than about 2 and still more preferably, greater than about 3.
- Headgroup-derivatized lipids can also be circulation-enhancing lipids, that is, the modifications directed to lipid toxicity buffering can also afford circulation enhancement. Accordingly, headgroup-derivatized lipids can inhibit clearance of liposomes from the circulatory systems of animals to which they have been administered. Liposomes are generally believed to be cleared from an animal's body by way of its reticuloendothelial system (RES). Avoiding RES clearance means that the frequency of liposome administration can be reduced, and that less of a liposome-associated bioactive agent need be administered to achieve desired serum levels of the agent. Enhanced circulation times can also allow targeting of liposomes to non-RES containing tissues.
- Liposome outer surfaces are believed to become coated with serum proteins, such as opsonins, in animals' circulatory systems. Without intending in any way to be limited by theory, it is believed that liposome clearance can be inhibited by modifying the outer surface of liposomes such that binding of serum proteins thereto is generally inhibited. Effective surface modification, that is, alterations to the outer surfaces of liposomes which result in inhibition of opsonization and RES uptake, is believed to be accomplished by incorporating into liposomal bilayers lipids whose polar headgroups have been derivatized by attachment thereto of a chemical moiety which can inhibit the binding of serum proteins to liposomes such that the pharmacokinetic behavior of the liposomes in the circulatory systems of animals is altered (see, e.g., Blume et al. (1993); Gabizon et al. (1993); Park et al. (1992); Woodle et al. U.S. Pat. No. 5,013,556; and, U.S. Pat. No. 4,837,028).
- Presently, dicarboxylic acids, such as glutaric, sebacic, succinic and tartaric acids, are preferred components of headgroup-derivatized lipids. Most preferably, the dicarboxylic acid is glutaric acid (“GA”). Accordingly, suitable headgroup-derivatized lipids include phosphatidylethanolamine-dicarboxylic acids such as dipalmitoyl phosphatidylethanolamine-glutaric acid (“DPPE-GA”), palmitoyloleoyl phosphatidylethanolamine-glutaric acid (“POPE-GA”) and dioleoyl phosphatidylethanolamine-glutaric acid (“DOPE-GA”). Most preferably, the derivatized lipid is DOPE-GA. The headgroup-derivatized can comprise from about 5 mole percent to about 50 mole percent of the liposome's lipid bilayer, but most preferably comprises about 10 mole percent of the bilayer.
- The liposomes of this invention can comprise one or more additional lipids, that is, lipids in addition to the sterol, underivatized PE, headgroup-derivatized lipid and etherlipid already present in the liposomes' bilayers. Additional lipids are selected for their ability to adapt compatible packing conformations with the other lipid components of the bilayer such that the lipid constituents are tightly packed and release of the lipids from the bilayer is inhibited. Lipid-based factors contributing to compatible packing conformations are well known to ordinarily skilled artisans and include, without limitation, acyl chain length and degree of unsaturation, as well as the headgroup size and charge. Accordingly, suitable additional lipids, including various phosphatidylcholines (“PC's”) such as egg phosphatidylcholine (“EPC”) or dioleoyl phosphatidylcholine (“DOPC”) can be selected by ordinarily skilled artisans without undue experimentation.
- Preferred embodiments of this invention have the underivatized PE being DOPE, the sterol being cholesterol (“chol”), the etherlipid being ET-18-OCH3 and the headgroup-derivatized lipid being DOPE-GA. Most preferably, presently, the liposome comprises DOPE, chol, ET-18-O—CH3 in a respective molar ratio of 4:3:1:2, wherein DOPE comprises 40 mole % of the liposomes' bilayers, chol 30% mole, DOPE-
GA 10 mole % and theetherlipid 20 mole %. Preferably, the liposomes are unilamellar and have an average diameter of from about 50 nm to about 200 nm, “average” meaning that the median diameter of a population of this invention's liposomes is between 50 and 200 nm. - The liposome can comprise an additional bioactive agent, that is, a bioactive agent in addition to the etherlipid. A “bioactive agent” is any compound or composition of matter that can be administered to animals, preferably humans. Such agents can have biological activity in animals; the agents can also be used diagnostically in the animals.
- Bioactive agents which may be associated with liposomes include, but are not limited to: antiviral agents such as acyclovir, zidovudine and the interferons; antibacterial agents such as aminoglycosides, cephalosporins and tetracyclines; antifungal agents such as polyene antibiotics, imidazoles and triazoles; antimetabolic agents such as folic acid, and purine and pyrimidine analogs; antineoplastic agents such as the anthracycline antibiotics and plant alkaloids; sterols such as cholesterol; carbohydrates, e.g., sugars and starches; amino acids, peptides, proteins such as cell receptor proteins, immunoglobulins, enzymes, hormones, neurotransmitters and glycoproteins; dyes; radiolabels such as radioisotopes and radioisotope-labelled compounds; radiopaque compounds; fluorescent compounds; mydriatic compounds; bronchodilators; local anesthetics; and the like.
- Liposomal bioactive agent formulations can enhance the therapeutic index of the bioactive agent, for example by buffering the agent's toxicity. Liposomes can also reduce the rate at which a bioactive agent is cleared from the circulation of animals. Accordingly, liposomal formulation of bioactive agents can mean that less of the agent need be administered to achieve the desired effect. Additional bioactive agents preferred for the liposome of this invention include antimicrobial, anti-inflammatory and antineoplastic agents, or therapeutic lipids, for example, ceramides. Most preferably, the additional bioactive agent is an antineoplastic agent.
- Liposomes can be loaded with one or more biologically active agents by solubilizing the agent in the lipid or aqueous phase used to prepare the liposomes. Alternatively, ionizable bioactive agents can be loaded into liposomes by first forming the liposomes, establishing an electrochemical potential, e.g., by way of a pH gradient, across the outermost liposomal bilayer, and then adding the ionizable agent to the aqueous medium external to the liposome (see Bally et al. U.S. Pat. No. 5,077,056 and WO86/01102).
- The liposome of this invention can be dehydrated, stored and then reconstituted such that a substantial portion of its internal contents are retained. Liposomal dehydration generally requires use of a hydrophilic drying protectant such as a disaccharide sugar at both the inside and outside surfaces of the liposome bilayers (see U.S. Pat. No. 4,880,635). This hydrophilic compound is generally believed to prevent the rearrangement of the lipids in the liposome, so that the size and contents are maintained during the drying procedure and through subsequent rehydration. Appropriate qualities for such drying protectants are that they be strong hydrogen bond acceptors, and possess stereochemical features that preserve the intramolecular spacing of the liposome bilayer components. Alternatively, the drying protectant can be omitted if the liposome preparation is not frozen prior to dehydration, and sufficient water remains in the preparation subsequent to dehydration.
- Also provided herein is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the liposome of this invention. “Pharmaceutically acceptable carriers” as used herein are those media generally acceptable for use in connection with the administration of lipids and liposomes, including liposomal bioactive agent formulations, to animals, including humans. Pharmaceutically acceptable carriers are generally formulated according to a number of factors well within the purview of the ordinarily skilled artisan to determine and account for, including without limitation: the particular liposomal bioactive agent used, its concentration, stability and intended bioavailability; the disease, disorder or condition being treated with the liposomal composition; the subject, its age, size and general condition; and the composition's intended route of administration, e.g., nasal, oral, ophthalmic, topical, transdermal, vaginal, subcutaneous, intramammary, intraperitoneal, intravenous, or intramuscular (see, for example, Nairn (1985)). Typical pharmaceutically acceptable carriers used in parenteral bioactive agent administration include, for example, D5W, an aqueous solution containing 5% weight by volume of dextrose, and physiological saline. Pharmaceutically acceptable carriers can contain additional ingredients, for example those which enhance the stability of the active ingredients included, such as preservatives and anti-oxidants.
- Further provided is a method of treating a mammal afflicted with a cancer, e.g., a brain, breast, lung, colon or ovarian cancer, or a leukemia, lymphoma, sarcoma, carcinoma, which comprises administering the pharmaceutical composition of this invention to the mammal, etherlipids being believed to be selectively cytotoxic to tumor cells. Generally, liposomal etherlipids can be used to treat cancers treated with free, that is, nonliposomal, etherlipids. However, encapsulation of an etherlipid in a liposome can enhance its therapeutic index, and therefore make the liposomal etherlipid a more effective treatment.
- An amount of the composition comprising an anticancer effective amount of the etherlipid, typically from about 0.1 to about 1000 mg of the lipid per kg of the mammal's body, is administered, preferably intravenously. For the purposes of this invention, “anticancer effective amounts” of liposomal etherlipids are amounts effective to inhibit, ameliorate, lessen or prevent establishment, growth, metastasis or invasion of one or more cancers in animals to which the etherlipids have been administered. Anddticancer effective amounts are generally chosen in accordance with a number of factors, e.g., the age, size and general condition of the subject, the cancer being treated and the intended route of administration, and determined by a variety of means, for example, dose ranging trials, well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention. Antineoplastic effective amounts of the liposomal etherlipid of this invention are about the same as such amounts of free, nonliposomal, etherlipids.
- Preferably, the liposome administered is a unilamellar liposome having an average diameter of from about 50 nm to about 200 nm. The anti-cancer treatment method can include administration of one or more bioactive agents in addition to the liposomal etherlipid, these additional agents preferably, but not necessarily, being included in the same liposome as the etherlipid. The additional bioactive agents, which can be entrapped in liposomes' internal compartments or sequestered in their lipid bilayers, are preferably, but not necessarily, anticancer agents or cellular growth promoting factors.
- This invention also provides a method of treating a mammal afflicted with an antiinflammatory disorder, e.g., arthritic conditions, asthmatic disorders and allergic reactions, comprising administering to the mammal an amount of the pharmaceutical composition provided herein sufficient to contain an anti-inflammation effective amount of the liposomal etherlipid. Inflammation is a process of cytological and histological reactions occurring in affected blood vessels, and surrounding tissues, in response to an injury (see, e.g.,Stedman's Medical Dictionary (Illustrated) (1982)). Inflammatory responses to such stimuli include local reactions and resulting morphological changes, destruction or removal of injurious materials and activation of repair mechanisms. Thus, inflammation can be part of the process by which animals heal themselves.
- However, inflammation can also occur in response to abnormal physiological stimuli, and can cause problems in the body. Joints, for example, become inflamed in arthritic conditions such as gout, filary arthritis, rheumatoid arthritis and Lyme disease (see, e.g.,Stedman's Medical Dictionary (Illustrated), supra at pages 123-124). These states may be characterized by the extravasation of cells, i.e, the egress of cells from the circulation into the inflamed area. Agents which can inhibit such extravasation, or which can otherwise inhibit inflammatory responses to abnormal physiological stimuli, can be used to ameliorate the inflammation. An “anti-inflammation effective amount” of a liposomal etherlipid, typically from about 0.1 mg to about 1000 mg per kg of a treated mammal's body weight, is any amount of the etherlipid effective to ameliorate, inhibit or prevent inflammatory responses or reactions in animals afflicted with conditions characterized by abnormal inflammation, i.e., inflammation which is in response to abnormal physiological stimuli and which is not part of the body's normal repair processes in response to an injury.
- This invention will be better understood from the following examples. However, those of ordinary skill in the art will readily understand that these examples are merely illustrative of the invention as defined in the claims which follow thereafter.
- D and L etherlipid stereoisomers can be prepared in small quantities by techniques well known to those of ordinary skill in the art. These methods have been utilized to prepare L etherlipid. However, sufficient quantities of the D etherlipid of sufficient purity for in vitro and in vivo experiments were not commercially available. Non-limiting exemplary techniques are described in Examples 1 and 2.
- Stereospecific Synthesis of L-ET18OCH3 (L-edelfosine)
- The synthesis of the L optical isomer of ET18OCH3 (L-edelfosine) is a multi-step process. First, n-Octadecylalcohol is reacted with Mesylchloride to form n-Octadecylmesylate. After the reaction is complete, the mother liquor is concentrated until a solid residue is obtained. This residue is the first intermediate and is purified by crystallization and washed.
- The next step involves reacting the n-Octadecylmesylate with 2,3-Isopropylidene-sn-glycerol, followed by hydrolysis to give 1-O-Octadecyl-sn-glycerol. The 1-O-Octadecyl-sn-glycerol is purified by crystallization, washed and dried.
- Next, the 1-O-Octadecyl-sn-glycerol is reacted with triphenylmethylchloride (tritylchloride). The reaction mixture in this step is worked up and concentrated. The 1-O-Octadecyl-3-O-trityl-sn-glycerol product is crystallized and washed.
- The 1-O-Octadecyl-3-O-trityl-sn-glycerol is reacted with Methyliodide to form a 1-O-Octadecyl-2-O-methyl-3-O-trityl-sn-glycerol product. After crystallyzation of the product, the trityl group is hydrolyzed to give 1-O-Octadecyl-2-O-methyl-sn-glycerol, which is subsequently purified by chromatography and crystallization.
- The 1-O-Octadecyl-2-O-methyl-sn-glycerol prepared above is reacted with Phosphorus oxychloride and then with Choline tosylate to form the crude Ether Lipid. The reaction mixture is worked up and concentrated under vacuum. The crude Ether Lipid is obtained by crystallization, centrifugation and washing.
- This multi-step reaction is summarized on FIG. 1.
- Stereospecific Synthesis of D-ET18OCH3 (D-edelfosine)
- In the first step of the multi-step synthesis of the D optical isomer of ET18OCH3 (D-edelfosine), n-Octadecylalcohol is reacted with Mesylchloride to form n-Octadecylmesylate. The mother liquor is concentrated until a solid residue is obtained. This residue is purified by crystallization and washed.
- The second step involves reacting the n-Octadecylmesylate with 1,2-Isopropylidene-sn-glycerol, followed by hydrolysis to give 1-O-Octadecyl-sn-glycerol. The 1-O-Octadecyl-sn-glycerol is purified by crystallization, washed and dried.
- The third step involves reacting 1-O-Octadecyl-sn-glycerol with triphenylmethylchloride (tritylchloride). The reaction mixture in this step is worked up and concentrated. The 1-O-Octadecyl-3-O-trityl-sn-glycerol product is crystallized and washed.
- The fourth step involves reacting the 1-O-Octadecyl-3-O-trityl-sn-glycerol with Methyliodide to form a 1-O-Octadecyl-2-O-methyl-3-O-trityl-sn-glycerol product. After crystallyzation of the product, the trityl group is hydrolyzed to give 1-O-Octadecyl-2-O-methyl-sn-glycerol, which is subsequently purified by chromatography and crystallization.
- The fifth step involves reacting 1-O-Octadecyl-2-O-methyl-sn-glycerol with Phosphorus oxychloride and then with Choline tosylate to form the crude Ether Lipid. The reaction mixture is worked up and concentrated under vacuum. The crude Ether Lipid is obtained by crystallization, centrifugation and washing.
- Liposomal formulations in accordance with the invention were prepared and evaluated as described in the following examples.
- Platelet Aggregation Assay
- Liposomal formulations were prepared as described in U.S. Pat. No. 5,762,958, incorporated herein by reference.
- The platelet aggregation effect of the liposomes in the whole blood of various mammals was evaluated using a CHRONO-LOG Dual Chamber Whole Blood Aggregometer Model 560, according to the following protocol:
- Venous blood was collected using 3.8% sodium citrate in a Vacutainer. Dilution ratio is 1 to 9 (citrate solution: blood). The effect of D and L etherlipid and liiposmes containing them on aggregation of platelets from rats, dogs, monkeys and humans was tested.
- Immediately following collection the blood was mix by gentle inversion (maintain at room temperature).
Prewarm 500 ul saline in disposable plastic cuvettes. Add 500 ul whole blood or PRP. Add disposable siliconized mini stir bar. Warmdiluted blood 5 min at 37° C. prior to testing. Add test samples to aggregation chambers and insert impedance probes. - Platelet aggregation response was determined by increased resistance using an impedance electrode in a platelet suspension. Resistance measurements were taken 6-8 minutes after addition of the test article to 1 ml whole blood or platelet rich plasma (PRP). The results of the evaluations are reported in Table 1.
TABLE 1 Platelet Aggregation Response in Whole Blood Dog Blood Rat Blood Human Blood Response Response Response Treatment Concentration (Ω) (Ω) (Ω) L- ELL 100 μM 8.5 0 0 D- ELL 100 μM 0 0 0 PAF 0.05 μM 14.8 0 6.0 ADP 20 μM 4.0 2.0 6.3 collagen 20 μg/ μL 12 34.1 36 - The results reported in Table 1 show that while there was no platelet aggregation response in the whole rat and human blood from either the D or L ether lipid, there was a stereospecific response to the L-ether lipid in whole dog blood (the reactions to PAF, ADP and collagen to demonstrate the acceptability of each platelet preparation for testing).
- To further investigate the platelet aggregation response triggered by the L-ether lipid in dog whole blood, the effect of a compound (CV-6209) that binds PAF binding sites on dog blood platelets was studied. The results are reported in Table 2.
TABLE 2 Platelet Aggregation Response in Dog Whole Blood Treatment Concentration (μM) Dog Blood Response (Ω) PAF 0.05 23.5 CV-6209/PAF 0.25/0.05 0 CV-6209/PAF 0.10/0.05 18.5 L- ether lipid 100 18 CV-6209/L-ether lipid 0.25/100 0 CV-6209/L-ether lipid 0.10/0.05 12.5 - The similar effects of the CV-6209 blinding molecule on the platelet aggregation response induced by PAF and L-etherlipid suggest that the molecules utilize the same binding sites on the dog blood platelets, and that the mechanisms by which molecules induce platelet aggregation are similar. Confirming the results in Example 3, the data in Table 2 indicates that dog blood platelets cannot distinguish between PAF and L-ether lipid.
- Two liposomal formulations differing only in the chirality of ether lipid component were prepared, and their toxicity on C57/BL6 mice (3-10 per group) was studied. Groups of female C57/BL6 mice weighing 16-20 g were injected i.v. with various doses of ELL-12 (L or D) diluted in PBS. Single dose i.v. toxicity, using doses of 150 or 200 mg/kg of L or D ELL-12 was evaluated to determine the maximally tolerated dose (MTD=dose lethal in less than or equal to 10% of the test mice). The multiple dose MTD was determined by administering 50-150 mg/kg L or D ELL-12 i.v. once per day for 5 consecutive days. The mice were weighed and observed twice weekly and mortality was recorded daily. Experiments were terminated 30 days after the treatment. The results are reported in Tables 3. L and D isomers of ET-18-OCH3 formulated in ELL-12 differed in vivo when adminsitered intraveneously. L-ELL-12 exhibited less acute toxicity than D-ELL-12 when administered i.V.
TABLE 3 Toxicity of Stereoisomeric Ether Lipid Liposomal Formulations on C57/BL6 Mice Dose Number of Survivors/Total Mice per Group mg/kg ELL-12(L) ELL-12(D) i.v. x 1 150 3/3 3/3 200 1/3 0/3 iv. x 5 daily 50 5/5 5/5 75 5/5 0/5 100 1/5 0/5 - The relative activity and toxicity of the two optical isomers of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (EL; optical isomers L-EL and D-EL shown in Formulas I and II below) was investigated in this study. Accordingly, this study was designed to evaluate the activity of each optical isomer of EL, and the racemic mixture using a standardized in vitro growth inhibition assay with a diverse tumor cell line panel including cell lines expressing multiple drug resistance. Hemolysis of washed rat red blood cells in vitro was used as an assay of the potential toxicity of the test compounds.
- The anti-tumor activities of the D and L etherlipid were evaluated against A549, a human non-small cell lung carcinoma cell line; MCF 7, a human breast carcinoma line and MCF 7/adr, multi-drug resistant human breast carcinoma; were obtained from the DCT Tumor Repository (NCI-Frederick Cancer Research Facility, Frederick, Md.). U-937, a human histiocytic lymphoma cell line, was obtained from the American Type Culture Collection. Stock cultures of these human cell lines were maintained in RPMI 1640 tissue culture media (Life Technologies, Gaithersburg, Md.) supplemented with 10% heat inactivated fetal bovine serum (Life Technologies) and 10 mM HEPES (Life Technologies). Cultures were maintained in exponential growth in a humidified incubator with 5% CO2 and were passaged twice weekly. L1210 and L1210/vmdr, murine lymphocytic leukemias, (Yale University School of Medicine). L1210/vmdr, a selected line of L1210, was transfected with a plasmid (pHaMDR1/A) containing the mdr I gene.
- A Sulforhodamine B (SRB) assay was employed to determine relative in vitro drug sensitivity using the GI50 parameter (the concentration of drug which inhibits
cell growth 50%). The detailed methodology of the SRB assay is described elsewhere (2,3). Briefly, 96-well microtiter plates were inoculated with 100 ul of the above cell lines at optimal cell densities, 3500-15,000 cells/well, in medium (RPMI 1640 with L-glutamine (Mediatech, Herndon, Va.)) supplemented with 10% fetal bovine serum (Life Technologies) for all cell lines. The plates were then incubated for 24 hours at 37° C., 100% humidity, and 5% CO2. After the 24 hour incubation, 100 μl of medium was added to the designated time zero plates, then the plates containing adherent cell lines were acid fixed with 50 ul of 50% trichloroacetic acid (wt/vol) (Sigma, St. Louis, Mo.) and refrigerated at 4° C. for 1 hour (the suspension cell lines were acid fixed with 80% trichloroacetic acid). The supernatant was discarded and the plates were rinsed 6 times with water and air dried. Then the test compound was added (100 ul aliquots) to the remaining (non-fixed) plates at 2 times the predetermined highest concentration and serially diluted across the plates. Growth control wells received an additional 100 ul of medium. There were triplicate wells on each plate and duplicate plates (6 representative wells) for each drug concentration. The cells were then incubated for 72 hours under the above conditions. The treated plates were acid fixed, rinsed and dried as above. One hundred microliters of 0.4% SRB (Sigma) in 1% acetic acid (Sigma) was added to the plates and incubated at room temperature for 10 minutes. Unbound stain was removed by rinsing theplates 3 times with 1% acetic acid. The plates were air dried for 24 hours. The bound stain was solubilized with 100 ul of 10 mM Tris buffer (Sigma) and the optical density was read spectrophotometrically at 490 nm (Microplate Reader Model 3550-UV, Biorad, Hercules, Calif.). The raw optical density data was imported into an Excel (Microsoft, Redmond, Wash.) spreadsheet to determine dose responses. Percent growth was calculated as follows: (T−T0)/(C−T0)×100 where (T)=mean optical density of treated wells at a given drug concentration, (T0)=mean optical density of time zero wells, and (C)=mean optical density of control wells, or if T<T0 where cell killing has occurred, then percent cell death can be calculated as follows: (T−T0)/(T0)×100. By varying drug concentration, dose response curves were generated and the GI50 values were calculated. The GI50 values for each experiment were calculated using data obtained from three duplicate wells on two separate plates. The mean GI50 values and standard deviations were then calculated from the GI50's from each independent experiment. -
- The complete hemolysis control was accomplished by repeated freeze-thaw cycles until the resulting pellet was absent or white. To better compare the hemolytic capabilities of the drugs, all drug concentrations were converted to uM. To account for interday variability of the 4% RBC solution, results were normalized to 0.4 OD. Where applicable, HI50 concentrations were calculated using WinNonlin version 1.1 Model 106 (sigmoid Emax)
- The results of the in vitro growth inhibition study (SRB assay) are reported in Table 4, while the results of the in vitro hemolysis assay are graphically depicted in FIG. 2. Table 4 shows that the two optical isomers and the racemic mixture had generally equivalent activity against all cell lines (GI50's ranging from about 1.5 to 29 M for the different cell lines) with the exception of the L1210/vmdr line in which D-EL showed a slight but statistically significant greater activity compared to L-EL and the racemate. Both isomers and racemic mixture were equally hemolytic to washed rat red blood cells in vitro with H50's ranging from 15.06 to 16.19 μM.
TABLE 4 In vitro growth inhibition after 72 hrs treatment GI50 (μM ± sd) Compound A549 Lewis Lung MCF7 MCF7/adr L1210 L1210/vmdr U937 L-EL 9.07 ± 0.39 29.13 ± 2.05 18.57 ± 4.57 27.95 ± 2.10 4.77 ± 0.41 8.77 ± 1.47 1.53 ± 0.4 D-EL 7.96 ± 0.57 25.45 ± 0.95 14.60 ± 5.92 25.12 ± 1.69 3.60 ± 1.59 4.87 ± 0.77b 1.41 ± 0.2 rac-EL 8.36 ± 0.67 27.05 ± 1.98 15.86 ± 6.41 27.83 ± 0.30 4.18 ± 1.38 6.09 ± 2.15 1.50 ± 0.2 - P388 Murine Leukemia. Female CDF1 mice (18-20 g) were injected i.p. with 1×105 P388 cells in 0.5 ml PBS on
day 0. Mice were randomly divided into groups (n=10) and treated i.p. with control or 50 mg/kg ELL-12 (L or D) on days 1-10 post inoculation. Mortality was observed daily and mean survival time (MST) was calculated. FIG. 3 demonstrates that D and L ELL-12 administered i.p. were equally effective against P388 leukemia. - B16/F10 Murine Melanoma. In three separate experiments, female C57/BL6 (16-20 g) mice were injected i.v. with 5×104 B16/F10 cells on
day 0. Mice were randomly divided into treatment groups (n=10) and treated i.v. with 6.25-12.5 mg/kg ELL-12 (LI or D) or control ondays days 21 or 25 post inoculation, lungs were removed, fixed in 10% formalin, and tumor nodules counted in a blind fashion using a magnifier. - Due to module encroachment, the precise number of nodules was difficult to determine when counts were 30 or more per lung. The mean number of nodules per treatment group within each experiment was calculated. When the tumor nodule count was more than 30 nodules per lung, it was recorded as “30” for the calculation. Student's t-test was used to compare ELL-12 (L) vs. (D). FIG. 4 demonstrates that the L isomer liposome formulation, when administered against established B16/F10 lung tumors, significantly (p<0.05) reduced the mean number of tumor nodules when compared to control or the D isomer liposome formulation.
- Hemolytic Activity. Hemolysis was assessed using washed red blood cells from Fisher rats that were adjusted to a cell density of 1×108 cells/ml. Samples were incubated at 37° C. for 30 minutes and certrifuged to pellet cells. Absorbances for the supernatants were measured at 550 nm and the results were expressed as percent hemolysis elicited by 1 mg/ml of ether lipid standard.
- Cell Cycle Studies. Fixation and staining were performed as previously described (Exp. Cell Res. 207: 142-151). Briefly, 2×106 cells were collected and pelleted by centrifugation (1000 rpm, 4° C., 5 min). The cells were resuspended in 1 ml cold PBS (1×) and fixed by adding 4 ml of chilled absolute EtOH (−20° C.). Cells were stored at −20° C. To stain, the fixed cells were pelleted (1000 rpm, 5 min) and resuspended in 1 ml PBS. One hundred μl of a 200 μg/ml RNAase (DNAase free), boiled 5-10 minutes before use, was added and the mixture incubated at 37° C. for 30 minutes. Propidium iodide (100 μl of a 1 mg/ml stock) was added and the samples were transferred to 12×75 Falcon tubes and read after 5-10 minutes. FIG. 5.
- Analysis of CD Expression. Monoclonal CD11b-PE was purchased from Ancell (Bayport, Minn.) and CD71-FITC and CD82-PE were purchased from Pharmingen (San Diego, Calif.). Monclonal IgG1 PE- or FITC-conjugated raised against trinitrophenol were used as iso-type controls to assess any nonspecific binding. U-937 (human histiocytic lyphoma) cells, from ATCC (Manassas, Va.) were harvested and centrifuged at 1000 rpm, 4° C., and washed twice in Dulbecco's PBS without Mg2+ or Ca2+ (DPBS, from Life Technologies) supplemented with 0.1% sodium azide (Sigma Chemicals) and 1% heat inactivated fetal bovine serum (washing buffer). 1×106 cells were aliquoted into Eppendorf tubes to a total volume of 100 μl in cell staining buffer (PBS without Mg or Ca, supplemented with 0.1% sodium azide, 1% heat inactivated fetal bovine serum and 5% mouse serum). The appropriate dilution of conjugated monoclonal antibody or conjugated iso-type control antibody was added to 1×106 cells (2.5 μl of CD11b or 20 μl of CD71 or CD82 were used according to the protocol supplied by the manufacturer), and the samples were incubated on ice, in the dark, for 60 min. Cells were then washed twice with washing buffer, fixed in 4% p-formaldehyde in PBS for 10 min, resuspended in washing buffer and analyzed by FACScan. FIGS. 6 and 7.
- Although the invention has been described with reference to specific examples and embodiments, various changes, substitutions, and/or omissions may be made without departing from the spirit and scope of the invention defined in the appended claims.
Claims (22)
1. A liposome having a lipid bilayer, said lipid bilayer comprising an optically active ether lipid component, said ether lipid component being selected from the group consisting of an L-ether lipid, a D-ether lipid and an unequal mixture of an L-ether lipid and a D-ether lipid.
2. The liposome of claim 1 further comprising:
(a) an underivatized phosphatidylcholine;
(b) a sterol;
(c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine; and
(d) wherein said liposome comprises greater than about 10 mole % to less than about 30 mole % of said ether stereoisomer.
3. The liposome of claim 1 , wherein said ether lipid stereoisomer is of the formula:
wherein Y1 is (CH2)n1(CH═CH)n2(CH2)n3(CH═CH)n4(CH2)n5(CH═CH)n6(CH2)n7(CH═CH)n8(CH2)n9, the sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 3 to 23, n1 is zero or an integer of from 1 to 22, n3 is zero or an integer of from 1 to 19, n5 is zero or an integer of from 1 to 16, n7 is zero or an integer of from zero to 16, n9 is zero or an integer of from 1 to 10, and each of n2, n4, n6 and 8 is independently zero or 1;
Y2 is CH3 or CO2H; and
Z is oxygen or sulfur.
4. The liposome of claim 1 wherein said liposome is unilamellar and has a diameter within the range of about 50-200 nm
5. The liposome of claim 2 , wherein the underivatized phosphatidylcholine is an unsaturated or partially unsaturated phosphatidylcholine.
6. The liposome of claim 5 , wherein the underivatized phosphatidylcholine is dioleoyl phosphatidylcholine.
7. The liposome of claim 2 , wherein the sterol is cholesterol.
8. The liposome of claim 2 , wherein the phosphatidylethanolamine is selected from the group consisting of dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and dioleoyl phosphatidylethanolamine.
9. The liposome of claim 8 , wherein the phosphatidylethanolamine is dioleoyl phosphatidylethanolamine.
10. The liposome of claim 2 , wherein the dicarboxylic acid is selected from the group consisting of glutaric acid, sebacic acid, succinic acid and tartaric acid.
11. The liposome of claim 10 , wherein the dicarboxylic acid is glutaric acid.
12. The liposome of claim 2 , wherein the phosphatidylethanolamine is dioleoyl phosphatidylethanolamine and the dicarboxylic acid is glutaric acid.
13. The liposome of claim 3 , wherein Y2 is CH3, Y1 is (CH2)n1, and Z is O.
16. The liposome of claim 15 , wherein the bilayer comprises about 20 mole percent of the ether lipid, about 10 mole percent of the phosphatidylethanolamine linked to a dicarboxylic acid, about 30 mole percent cholesterol and about 40 mole percent dioleoyl phosphatidylcholine.
17. The liposome of claim 1 , comprising an additional bioactive agent.
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the liposome of claim 1 .
19. A method of treating a mammal afflicted with a cancer which comprises administering to the mammal an amount of the pharmaceutical composition of claim 1 comprising from about 0.1 mg of the ether lipid per kg of the body weight of the mammal to about 1000 mg per kg, wherein the cancer is selected from the group consisting of lung cancers, brain cancers, colon cancers, ovarian cancers, breast cancers, leukemias, lymphomas, sarcomas and carcinomas.
20. The method of claim 19 , comprising administering to the mammal an additional biologically active agent.
21. The method of claim 20 , wherein the additional agent is selected from the group consisting of antineoplastic agents, antimicrobial agents, and hematopoietic cell growth stimulating agents.
22. The method of claim 19 , wherein the liposome is a unilamellar liposome having a diameter of from about 50 nm to about 200 nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/647,382 US20040047903A1 (en) | 1996-02-16 | 2003-08-26 | D and L etherlipid stereoisomers and liposomes |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/602,669 US5762958A (en) | 1994-10-14 | 1996-02-16 | Multilipid component ether lipid liposomes |
US09/017,440 US5965159A (en) | 1996-02-16 | 1998-02-02 | Etherlipid-containing multiple lipid liposomes |
US09/390,395 US6180137B1 (en) | 1996-02-16 | 1999-09-03 | Etherlipid-containing multiple lipid liposomes |
US09/540,050 US6667053B1 (en) | 1996-02-16 | 2000-03-31 | D and L etherlipid stereoisomers and liposomes |
US10/647,382 US20040047903A1 (en) | 1996-02-16 | 2003-08-26 | D and L etherlipid stereoisomers and liposomes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/540,050 Continuation US6667053B1 (en) | 1996-02-16 | 2000-03-31 | D and L etherlipid stereoisomers and liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040047903A1 true US20040047903A1 (en) | 2004-03-11 |
Family
ID=24153772
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/540,050 Expired - Fee Related US6667053B1 (en) | 1996-02-16 | 2000-03-31 | D and L etherlipid stereoisomers and liposomes |
US10/647,382 Abandoned US20040047903A1 (en) | 1996-02-16 | 2003-08-26 | D and L etherlipid stereoisomers and liposomes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/540,050 Expired - Fee Related US6667053B1 (en) | 1996-02-16 | 2000-03-31 | D and L etherlipid stereoisomers and liposomes |
Country Status (6)
Country | Link |
---|---|
US (2) | US6667053B1 (en) |
EP (1) | EP1267835A1 (en) |
JP (1) | JP2003528908A (en) |
AU (1) | AU2001255211A1 (en) |
CA (1) | CA2402864A1 (en) |
WO (1) | WO2001074333A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667053B1 (en) * | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
JP4417249B2 (en) * | 2002-06-19 | 2010-02-17 | 株式会社マルハニチロ水産 | Oral skin injury preventive and therapeutic agent containing diacylglyceryl ether |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
AU2007334775A1 (en) * | 2006-12-20 | 2008-06-26 | Universitatsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
US9442046B2 (en) | 2011-06-19 | 2016-09-13 | Abogen, Inc. | Device for sample collection |
WO2013156630A1 (en) * | 2012-04-20 | 2013-10-24 | Alphaptose Gmbh | S-enantiomer of a tri-substituted glycerol compound |
GB201208850D0 (en) * | 2012-05-18 | 2012-07-04 | Alphaptose Gmbh | Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis |
EP3160959B1 (en) * | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
EP4040149A1 (en) | 2015-02-09 | 2022-08-10 | Abogen, Inc. | Devices, solutions and methods for sample collection related applications, analysis and diagnosis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182902A (en) * | 1973-12-27 | 1980-01-08 | Siegfried Aktiengesellschaft | Novel cholesterol-lowering compounds |
US5444052A (en) * | 1991-12-11 | 1995-08-22 | Temple University Of The Commonwealth System Of Higher Education | Amphotericin B composition with enhanced fungal activity |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
US5583052A (en) * | 1994-05-23 | 1996-12-10 | The Liposome Company, Inc. | Formulation preparation device |
US5616341A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal antineoplastic agents |
US5703117A (en) * | 1995-09-12 | 1997-12-30 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US5908835A (en) * | 1992-11-10 | 1999-06-01 | Rhone-Poulenc Rorer, S.A. | Anti-tumor compositions containing taxane derivatives |
US6153736A (en) * | 1995-09-27 | 2000-11-28 | The Liposome Company, Inc. | Modified ether glyceroglycolipids |
US6667053B1 (en) * | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2009343C3 (en) | 1970-02-27 | 1980-10-23 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Use of lysolecithins as immunological adjuvants |
US4163748A (en) | 1973-09-06 | 1979-08-07 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Propane-1,3-diol phosphatides and method of preparing the same |
US4159988A (en) | 1974-08-06 | 1979-07-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Synthetic phospholipids, a process for their manufacture and their use |
DE2619686C2 (en) | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Use of a lysolecithin for tumor treatment |
DE3011738A1 (en) | 1980-03-26 | 1981-10-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | NEW GLYCERIN-3-PHOSPHORIC ACID HALOGYL ALTER |
DE3239858A1 (en) | 1982-07-06 | 1984-01-12 | Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | NEW D-MANNITE DERIVATIVES AS STARTING PRODUCTS FOR THE SYNTHESIS OF PHOSPHOLIPIDES |
JPS6122020A (en) | 1984-07-09 | 1986-01-30 | Takeda Chem Ind Ltd | Antitumor agent |
JPS6172294A (en) | 1984-09-17 | 1986-04-14 | 松下電器産業株式会社 | Display unit |
US4983397A (en) | 1985-08-19 | 1991-01-08 | Board Of Regents, University Of Texas System | Pharmaceutical compositions consisting of acylated phospholipids |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4965391A (en) | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE4111105A1 (en) | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | NEW ERUCYL, BRASSIDYL AND NERVONYL DERIVATIVES |
US5277913A (en) | 1991-09-09 | 1994-01-11 | Thompson David H | Liposomal delivery system with photoactivatable triggered release |
DE4132345A1 (en) | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Medicament compsns. for intravenous admin. of lytic agents - used for treatment of tumours, auto-immune disorders, multiple sclerosis, etc. |
WO1993008202A1 (en) * | 1991-10-23 | 1993-04-29 | National Research Council Of Canada | Formation of stable liposomes from lipid extracts of archaeobacteria (archaea) |
JPH08510748A (en) | 1993-05-21 | 1996-11-12 | ザ リポソーム カンパニー、インコーポレーテッド | Reduction of physiological side effects induced by liposomes |
WO1996011670A1 (en) | 1994-10-14 | 1996-04-25 | The Liposome Company, Inc. | Ether lipid liposomes and their therapeutic use |
US5965159A (en) | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US5932242A (en) | 1996-10-15 | 1999-08-03 | The Liposome Company, Inc. | Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof |
-
2000
- 2000-03-31 US US09/540,050 patent/US6667053B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 CA CA002402864A patent/CA2402864A1/en not_active Abandoned
- 2001-03-30 AU AU2001255211A patent/AU2001255211A1/en not_active Abandoned
- 2001-03-30 EP EP01928341A patent/EP1267835A1/en not_active Withdrawn
- 2001-03-30 WO PCT/US2001/010304 patent/WO2001074333A1/en not_active Application Discontinuation
- 2001-03-30 JP JP2001572078A patent/JP2003528908A/en active Pending
-
2003
- 2003-08-26 US US10/647,382 patent/US20040047903A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182902A (en) * | 1973-12-27 | 1980-01-08 | Siegfried Aktiengesellschaft | Novel cholesterol-lowering compounds |
US5616341A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal antineoplastic agents |
US5744158A (en) * | 1987-03-05 | 1998-04-28 | The Liposome Company, Inc. | Methods of treatment using high drug-lipid formulations of liposomal-antineoplastic agents |
US5795589A (en) * | 1987-03-05 | 1998-08-18 | The Liposome Company, Inc. | Liposomal antineoplastic agent compositions |
US6083530A (en) * | 1987-03-05 | 2000-07-04 | The Liposome Company, Inc. | High drug:lipid formulations of liposomal-antineoplastic agents |
US5444052A (en) * | 1991-12-11 | 1995-08-22 | Temple University Of The Commonwealth System Of Higher Education | Amphotericin B composition with enhanced fungal activity |
US5908835A (en) * | 1992-11-10 | 1999-06-01 | Rhone-Poulenc Rorer, S.A. | Anti-tumor compositions containing taxane derivatives |
US5583052A (en) * | 1994-05-23 | 1996-12-10 | The Liposome Company, Inc. | Formulation preparation device |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
US5703117A (en) * | 1995-09-12 | 1997-12-30 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US6153736A (en) * | 1995-09-27 | 2000-11-28 | The Liposome Company, Inc. | Modified ether glyceroglycolipids |
US6667053B1 (en) * | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
Also Published As
Publication number | Publication date |
---|---|
CA2402864A1 (en) | 2001-10-11 |
US6667053B1 (en) | 2003-12-23 |
WO2001074333A1 (en) | 2001-10-11 |
JP2003528908A (en) | 2003-09-30 |
EP1267835A1 (en) | 2003-01-02 |
AU2001255211A1 (en) | 2001-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0785773B1 (en) | Ether lipid liposomes and their therapeutic use | |
US6007839A (en) | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes | |
EP0742789B1 (en) | Pharmaceutically active compounds and liposomes, and methods of use therof | |
KR100386002B1 (en) | Hydrophobic taxane derivatives | |
US6120797A (en) | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery | |
US6667053B1 (en) | D and L etherlipid stereoisomers and liposomes | |
DE60105977T2 (en) | LIPIDEN-BASED SYSTEMS FOR DRUG DISPENSING | |
US6017557A (en) | Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof | |
US20050008664A1 (en) | Compositions and methods related to lipid:emodin formulations | |
US5965159A (en) | Etherlipid-containing multiple lipid liposomes | |
USRE39042E1 (en) | Etherlipid-containing multiple lipid liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDEUS PHARMA LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELAN PHARMACEUTICALS, INC.;REEL/FRAME:016080/0799 Effective date: 20040212 Owner name: ZENEUS PHARMA LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:MEDEUS PHARMA LIMITED;REEL/FRAME:016085/0075 Effective date: 20040922 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |